An insert device for delivery of pharmaceuticals
The intestinal insert device addresses the challenge of precise, long-lasting pharmaceutical delivery in the intestine by using an expandable CMC material to form a closure within the intestine, ensuring effective local administration and absorption of intestinal waste.
Patent Information
- Application Number
- PCT/EP2026/063246
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-05-07
- Filing Date
- 2026-05-07
- Publication Date
- 2026-11-12
AI Technical Summary
Existing methods for local administration of pharmaceuticals in the intestine face challenges in precise, long-lasting delivery to a defined surface area, with issues such as systemic side effects and difficulty in maintaining the active substance in place, especially for individuals with ostomies who experience continuous and uncontrollable excretion of intestinal waste.
A medicated intestinal insert device that expands radially upon absorption to form a closure within the intestine, capable of delivering pharmaceuticals and absorbing liquid while being withdrawn, using an absorbent material like carboxymethyl cellulose (CMC) to maintain contact with the intestinal mucosa and retain the active substance.
The device provides long-lasting, precise, and local administration of pharmaceuticals to the intestine, reducing systemic side effects and ensuring consistent exposure to the active substance, while overcoming the limitations of traditional administration methods.
Smart Images

Figure EP2026063246_12112026_PF_FP_ABST
Abstract
Description
[0001] An insert device for delivery of pharmaceuticals
[0002] Technical Field
[0003] The invention relates to an application device for local application of a pharmaceutical in the intestine. The application device is an insert device for insertion rectally or through an ostomy (ileostomy, colostomy, urostomy) of a human being, the device being configured to absorb intestinal fluid and waste inside the intestines of the human being, and / or configured to deliver pharmaceuticals to the intestines.
[0004] Background art
[0005] Several medical conditions can require pharmaceutical treatment of the intestine, e.g. inflammation of the intestine due to Crohn's and ulcerative colitis (colitis ulcerosa), pouchitis, infectious diseases including sexually transmitted infections and bacterial infections from food poisoning, hemorrhoids and polyps.
[0006] Pharmaceuticals used in the treatment of intestinal disorders include probiotics, steroids, Non-steroid anti-inflammatory drugs (NSAID), fecal transplants, immunosuppressive pharmaceuticals and antibiotics.
[0007] Treatments can have a mode of action systemically or locally and typical routes of administration include oral (systemic effect), stomal and rectal administration (with e.g. cream, ointment, tablets, liquids and suppositories). Several of the pharmaceuticals mentioned above, including steroids, can have a wide range of side effects, including metabolic side effects, which is why local treatment in the intestine can be preferable. However, local treatment via rectal or stomal administration using, e.g., creams, liquids and suppositories has limitations, as creams can only be applied to the distal part of the intestinal canal, and suppositories or liquids dissolve without control over the site of the drug release and only has a limited time of action due to excretion or absorption of the active substances.
[0008] An ostomy is an artificial intestinal opening where the part of the intestine, often the large intestine (colon) and sometimes part of the small intestine, is surgically removed due to illness or trauma, and the remaining part of the intestine is redirected through the abdominal wall and sutured to the skin, constituting the ostomy. Hereafter, the intestinal waste is emptied through the ostomy. Depending on the location along the intestinal tract where the stoma is created itmay be classified as an ileostomy emptying waste from the small intestine (ileum or jejunum), a colostomy emptying waste from the large intestine (colon) or a urostomy (emptying urine). All the above-mentioned localized ostomies may generally be known as ostomies or stomas.
[0009] Ostomies do not have a sphincter to control voluntary excretion of intestinal waste and therefore the ostomy is incontinent with continuous and uncontrollable excretion of intestinal waste. To collect the intestinal waste a stoma bag is attached to a person's stomach by an adhesive plate, at all times. However, the stoma bag has considerable disadvantages, such as mental stress of always having a stoma bag filled with intestinal waste adhered to the stomach, fear of leakage from the stoma bag, skin complications due to skin contact with intestinal waste, sounds and odors from filling the bag, and in general a lowered quality of life.
[0010] Besides stoma bags, people with colostomies have had the opportunity to use a plug for withholding solid stool in combination with flushing their intestines. This plug-solution is designed for withholding solid stool in a colostomy (stoma of the large intestine) and is not suited for use in an ileostomy because of the large volumes of liquid content that are produced in the ileum. This makes it difficult to seal the ileum properly. For the majority of people with an ileostomy, the intestinal waste is liquid and the volume is 500-1000 millilitre per day.
[0011] Furthermore, 62% of ileostomies are caused by inflammatory bowel disease (Morbus Crohn and Colitis ulcerosa), and many of them experience active inflammation in the remaining intestine, making them relevant candidates for local pharmaceutical treatment of their intestine, through their ostomy.
[0012] An absorbent insert devices for collecting liquid and semi-liquid intestinal waste inside the intestine of a human is described in WO 2022 / 207051, which is incorporated by reference in its entirety.
[0013] An absorbent insert ostomy device for insertion through an ostomy of a human being is described in WO 2023 / 152406 A2, which is incorporated by reference in its entirety.
[0014] An insertion and withdrawal system for inserting, subtracting, and containing an ostomy device is described in WO 2023 / 175202 Al, which is incorporated by reference in its entirety.Summary of the invention
[0015] There is thus a need for a device for local precise, and potentially long-lasting administration of pharmaceuticals to a defined surface area of the intestine.
[0016] Pharmaceuticals such as steroids, non-steroid anti-inflammatory drugs (NSAID), fecal transplants, immunosuppressive pharmaceuticals and antibiotics are typically used in the treatment of intestinal disorders such as inflammatory bowel diseases, infections such as proctitis or pouchitis, hemorrhoids and polyps.. Typical routes of administration include oral and rectal administration. Whereas oral administration has a systemic mode of action, rectal administration also provides localised effect of the administered substance. Local administration forms includesi cream, ointment, tablets, liquids, enema, and suppositories. Several of the pharmaceuticals, including steroids, have a wide range of side effects, including metabolic side effects. Local administration usually results in less side effects. However, it is difficult to administer a local steroid (such as e.g. cream, ointment, tablets and suppositories), precisely in the intestines and provide a delivery to a defined or wide surface area, with the administration being equally distributed to the desired area. Moreover, it is difficult to provide a long-lasting exposure of the active substance, as there is nothing to keep it in place against the intestinal wall / target area. Thus, there is a need for a device for long-lasting, precise and local administration of pharmaceuticals, microbiota, probiotics and active substances in the intestines.
[0017] The present invention solves the above problems by providing a medicated insert intestinal device for insertion rectally or through an ostomy of a human being. The insert intestinal device is able to deliver pharmaceuticals or active substances to the intestines, and / or absorb liquid in the intestine while forming a closure hereof, and with the ability to retain the majority of that liquid, while being withdrawn from the intestine. In particular, the present invention provides a drug delivery action for local treatment of intestinal disorders.
[0018] According to an aspect, the invention concerns an intestinal insert device, wherein said device comprises a pharmaceutical, a microbiome, a probiotic, or a faecal transplant.
[0019] According to another aspect, the invention concerns an intestinal insert device, wherein the device being configured to absorb intestinal waste of a human being, the device comprising:- an expandable elongated body comprising an absorbent material, - withdrawal means attached to the elongated body, and
[0020] - one or more pharmaceutical, microbiome, probiotic and / or faecal transplant.
[0021] According to another aspect, the invention concerns an active pharmaceutical agent for use in the treatment of an intestinal disorder or disease for administration through the intestinal insert device according to the invention.
[0022] The present disclosure therefore relates to an insert intestinal device suitable for insertion rectally and / or through a stoma of a subject such as a human being. The wording "through a stoma" may also be worded as "into a stoma" depending on how the stoma is made and how far into the opening the device protrudes. The device will enter into the stoma opening (the ostomy) and / or the anal opening and be positioned within the intestines (in case of e.g. an ileostomy). The device could both be said to be suitable for insertion through a stoma or anal opening of a subject such as a human being and / or suitable for insertion into a stoma or anal opening of a subject such as a human being.
[0023] A stoma may herein be a natural stoma or an artificially created opening in the body. An example of a natural stoma is the anus, and an example of an artificial stoma is an ileostomy. Behind the body opening is located a body canal such as the rectum, the colon, or the ileum. In one or more embodiments the stoma is a natural stoma. In one or more embodiments the stoma is the anus. In one or more embodiments, the stoma is an opening on the abdomen that can be connected to either the digestive or urinary system to allow waste (urine or faeces) to be diverted out of the body. In one or more embodiments, the stoma is an ileostomy.
[0024] In other words, the present invention provides a disposable absorbing application device that can also function as a closure for liquid and semi-liquid intestinal contents from artificial and natural intestinal openings. The invention is free from the physical and psychological drawbacks from stoma bags. The invention consists of an absorbent organ, shaped and constructed so that the organ expands in the intestine upon absorption to a radial diameter, but is easily extracted through a stoma and / or anal opening while retaining absorbed intestinal content. The invention is capable of absorbing large amounts of intestinal content.The absorbent insert intestinal device is configured to be placed inside such a body canal and form a closure of the body canal. In particular, the absorbent insert intestinal device as disclosed herein is suited for insertion through an ostomy and / or the anus and for placement inside e.g. the rectum or ileum of the subject. The absorbent insert intestinal device comprises an absorbent material for absorbing liquids, in particular intestinal waste of the subject.
[0025] The absorbent insert device is configured to be placed inside an intestinal canal and serve a function as a mean of drug delivery. The active substances can either be integrated or coated into the insert device, but the insert device is also suitable for absorbing, retaining and thereby exposing active substances in liquid or gelatinous form to the intestinal mucosa. Such liquids can be transferred to the insert device before or after insertion of the device through enema, irrigation or infusion and ensures an exposure in up to six hours which is the maximum use time of a single device.
[0026] The absorbent insert intestinal device comprises one or more withdrawal means e.g. attached to the elongated body at one end of said body, such that the device can be withdrawn with ease from the subject using said withdrawal means. The withdrawal means may be a string or a cord such that the insert device may be removed from the subject by pulling the string / cord. As an example, the string or cord may be made of cotton, nylon, silicone, rubber, polyester, and / or combinations thereof. However, other materials for the string / cord could be used. Preferably, the withdrawal means is configured to protrude from the stoma or anus, when the insert device is placed inside the body canal, such that the subject can pull the withdrawal means to remove the insert device from the body canal. Any of the embodiments of the insert device as described herein may be provided with the withdrawal means. To ensure the absorbent device stays in place, a button or similar may be attached to the end of the withdrawal means.
[0027] In general, tampon-like closures have the drawback that they typically have a small absorption capacity. If used in the intestine, this may result in intestinal waste not being able to be absorbed by the closure and thereby leak or accumulate behind the closure, which potentially leads to an increased pressure on the intestinal wall. The increased pressure can result in dilation of the intestine, or it can result in the closure being pushed out of the intestine, both of which are undesirable situations. A further challenge with a tampon-like closure is that the diameter of the stoma or anus is smaller than the elastic diameter of the intestine, wherebythere is a risk of squeezing the closure upon pulling it out through the stoma or anus, whereby some of the liquid intestinal waste is spilled. A more serious risk is the inability to remove the tampon-like closure from the stoma opening after it has expanded inside the intestine to a larger diameter than the stoma opening. For these reasons, no tampon-like solution has ever been commercialized for usage in ostomies. However, as demonstrated herein, the disclosure of the present invention has nicely solved these problems.
[0028] Carboxymethyl cellulose (CMC) or cellulose gum is a cellulose derivative with carboxymethyl groups (-CH2COOH) bound to some of the hydroxyl groups of the glucopyranose monomers that make up the cellulose backbone. It is often used as its sodium salt, sodium carboxymethyl cellulose.
[0029]
[0030] R = H or CH2CO2H
[0031] Schematic drawing of CMC - for illustrative purposes.
[0032] CMC is normally used in food as a viscosity modifier or thickener, and to stabilize emulsions in various products including ice cream. However, it has also found use in a constituent of many non-food products, such as toothpaste, laxatives, diet pills, water-based paints, detergents, textile sizing, reusable heat packs, various paper products, and also in leather crafting to help burnish the edges. It is used primarily because it has high viscosity, is nontoxic, and is generally considered to be hypoallergenic as the major source fibre is either softwood pulp or cotton linter.
[0033] Further, knitted fabric made of cellulose (e.g. cotton or viscose rayon) has also been used in various medical applications when converted into CMC, e.g. as a device for epistaxis where a poly-vinyl chloride (PVC) balloon is covered by CMC knitted fabric reinforced by nylon. The device is soaked in water to form a gel, this is inserted into the nose and the balloon inflated. The combination of the inflated balloon and the therapeutic effect of the CMC stops the bleeding. Such fabric has also been used as a dressing in surgical procedures. Such fabric mayalso be referred to as CMC Gelling Fibre Dressing, which as disclosed herein is referring to a sterile, single-use dressing which composed of sodium carboxymethylcellulose fibres for wounds with moderate to heavy exudate. The fibre in the dressing rapidly swells after absorbing the wound exudate to form a cohesive transparent gel. The gelling fibre can absorb and lock the exudate, and the bacteria and harmful substances in the exudate are also locked in the dressing, reducing the risk of wound infection and maceration, and maintaining the optimal moist healing environment.
[0034] By using CMC as at least part of the one or more absorbent materials, enables the device to enter the ostomy and / or the anus opening, expand radially and longitudinally to a configuration tailored to the dimension of the intestine while absorbing intestinal waste and retain the intestinal waste while being withdrawn through the stoma and / or anus. This also means that the device is configured to absorb and / or collect intestinal waste inside the intestine, such as the ileum and / or rectum, of the subject, and comprises an expandable elongated body having an initial length and comprising an absorbent material, and withdrawal means attached to the elongated body, wherein the expandable elongated body is configured to expand radially upon insertion into the intestine through the stoma and / or anus to form a leak-tight closure of the stoma and / or anus.
[0035] This means that the overall initial diameter (as seen in a cross section through the longitudinal axis of the device) of the device prior to insertion is smaller than or equal to the overall diameter (as seen in a cross section through the longitudinal axis of the device) of the device after it has been inserted into the stoma and / or anus and released. This can be done by using various compression means, such as utilising an insertion sleeve or applicator surrounding the absorbent material prior to insertion or by inclosing the absorbent material in foil or plastic that is dissolved when the device is inserted in the stoma and / or anus. The absorbent material hereby undergoes a change from a compressed state in which it has a size that makes it able to enter the stoma and / or anus to a non-compressed state (i.e. the material expands), such that it may make a (tight) closure of the stoma and / or anus e.g. by being placed against the inside walls of the ilium or by the intestinal mucosa folding tightly around the device.
[0036] It is important to choose an absorbent material, which is not irritating towards the mucus barrier of the intestines. Further, the material may not perforate or in any other way cause mechanical damage to the intestines, not may the chosen material dry out the mucus barrier ofthe intestines. Preferably the material should also expand when absorbing liquid to make a tight barrier abutting the mucus barrier of the intestines.
[0037] In these regards, CMC is a very suited material, as CMC is very soft both in dry and wet state. When the CMC gets wet, due to wetting from the mucosa and absorption of feces, it is converted into a cohesive gel. CMC fibres have a natural 'swelling' when it comes into contact with liquid. Further, CMC has a relatively high degree of 'retention', hereby holding on to the stool even when the device / elongated body is subjected to a slight pressure. Even further, as shown in the examples, CMC absorbs about 34 times its own weight in small intestine feces, which makes it especially suited for the purpose as disclosed herein.
[0038] A CMC material as disclosed herein preferably has the following parameters:
[0039] A mass per unit area (measured according to ISO 9073-1:1989) 120-180 g / m2
[0040] A liquid absorption (measured according to EN 13726-1:2002) of at least 15 g per 100 cm2.
[0041] A tensile strength in its dry state (measured according to ISO 13934-1:2013) of at least 3 Newton per centimetre.
[0042] A tensile strength in its wet state (measured according to ISO 13934-1:2013) of at least 0.2 Newton per centimetre.
[0043] A loss on drying (measured according to JYWN-QM-P02-SOP162) of no more than 25%. A heavy metal content (measured according to JYWN-QM-P02-SOP162) of no more than 20 microgram per gram.
[0044] The presently disclosed aspects solve the problem of how to withdraw an absorbent closure holding an amount of absorbed liquid content from a body canal out through a stoma or natural intestinal opening. This is problematic as natural or artificial intestinal openings may have a smaller diameter than the body canal, which makes it challenging to withdraw an absorbent closure through the opening, without squeezing the closure and thereby spilling some of the absorbed intestinal waste inside the body canal, e.g. intestine. The applicant has solved these challenges by providing an insert device that can be described by (at least) two diameters: a first diameter that could preferably be equal to or less than the diameter of the stoma of the subject, and a second diameter that could preferably approximately equal the diameter of the body canal, wherein the insert device is intended to be placed. Prior to insertion through the stomaan / or anus, the absorbent insert device is compressed to a size such that it can be inserted through the stoma and / or anus. After insertion and removal of the compressing force, the insert device preferably expands radially to largely conform to the diameter of the body canal behind the stoma and / or anus, wherein it is placed, in order to form a closure of said body canal.
[0045] Hence, subsequent to insertion, the insert device preferably expands to obtain the second diameter. However, even after expansion and absorption of intestinal waste, the insert device is still able to be withdrawn from the body canal out through the stoma and / or anus while retaining (ideally) all of the absorbed liquid content, or most of the liquid content. This ability is preferably achieved by configuring the insert device such that it conforms to the diameter of the stoma and / or anus, e.g. achieved by the first diameter, when pulled out of the body canal by means of the withdrawal means.
[0046] According to an embodiment, the first diameter may be about 0.1 - 2.5 cm or preferably about 0.5 - 2 cm.
[0047] According to an embodiment, the second diameter may be about 1-7 cm, or preferably about 2-5 cm.
[0048] Brief description of the drawings
[0049] Fig. 1A shows the absorbent insert intestinal device according to an embodiment, wherein the elongated body is curled around a longitudinal axis of the body to form a helix comprising a plurality of turns.
[0050] Fig. IB shows the absorbent insert intestinal device according to an embodiment, wherein the elongated body comprises a plurality of flexible protrusions extending radially from the body, such that the elongated body resembles a brush.
[0051] Fig. 1C shows the absorbent insert intestinal device according to an embodiment, wherein the elongated body of the insert device is provided as a flexible tube, which is preferably partly or entirely filled with the one or more absorbent materials.Fig. ID shows the absorbent insert intestinal device according to an embodiment, wherein the elongated body of the insert device is formed from a sheet or a strip, which is rolled into an elongated conical shape.
[0052] Fig. IE shows the absorbent insert intestinal device according to an embodiment, wherein the elongated body of the insert device is formed from a tube having a closed end, wherein the tube is folded one or more times inside itself.
[0053] Fig. IF shows the absorbent insert intestinal device according to an embodiment, wherein the elongated body of the insert device is formed from a plurality of cylinders, each cylinder comprising an absorbent material.
[0054] Figures 2A-2F shows a non-compressed state of the insert device according to the corresponding (compressed) embodiment of fig. 1A-1F.
[0055] Figures 3A-3F shows cross-sections of the embodiments shown in figures 1A-1F. These crosssections correspond to the compressed state of the insert device.
[0056] Figures 4A-4F shows cross-sections of the embodiments shown in figures 2A-2F. These crosssections correspond to the non-compressed state of the insert device.
[0057] Fig. 5A shows the absorbent insert intestinal device according to an embodiment, wherein the elongated body is formed from a sheet that is folded to form a wave-like pattern of crests and troughs.
[0058] Fig. 5B shows the absorbent insert intestinal device according to an embodiment, wherein the elongated body constitutes a cylinder that is folded one or more times.
[0059] Figure 6 shows directions of the expandable elongated body as disclosed herein.
[0060] Fig. 7A shows the absorbent insert intestinal device according to an embodiment, wherein the elongated body is in the compressed state.Fig. 7B shows the absorbent insert intestinal device according to an embodiment, wherein the elongated body is curled around a longitudinal axis of the body to form a helix comprising a plurality of turns and wherein the body further comprises a plurality of flexible protrusions extending radially from the body.
[0061] Fig. 7C shows the absorbent insert intestinal device according to an embodiment after withdrawal of the device from the subject.
[0062] Fig. 8A shows the absorbent insert intestinal device according to an embodiment, wherein the elongated body is curled around a longitudinal axis of the body to form a helix comprising a plurality of turns and wherein the elongated body comprises a plurality of flexible protrusions extending radially from the body, such that the elongated body further resembles a brush.
[0063] Figures 8B show a non-compressed state of the insert device according to the corresponding (compressed) embodiment of fig. 8A.
[0064] Figure 9 shows pictures from example 4, i.e. an insert device made of carboxymethyl cellulose covered with riboflavin (vitamin B2) in the form of a powder, before the insert device was compressed. The device is placed in a see-through plastic bag, filled with water. The riboflavin powder is fluorescent, illustrating that the powder is released in the entire length of the insert device when the device is unfolded (non-compressed), see figure 9 (top). Additionally, a commercial vaginal tampon powdered with riboflavin (vitamin B2), is shown in figure 9 (bottom).
[0065] Figure 10 shows a picture from example 5, i.e. an insert device made of carboxymethyl cellulose covered with riboflavin (vitamin B2) in the form of a powder, before the insert device was compressed. The device is then placed in a see-through plastic bag with perforations. This bag was then placed in a second see-through plastic bag filled with water.Detailed description of the invention
[0066] The description herein of any aspect or embodiment of the invention using terms such as "comprising", "having," "including," or "containing" with reference to an element or elements is intended to provide support for a similar aspect or embodiment of the invention that "consists of", "consists essentially of", or "substantially comprises" that particular element or elements, unless otherwise stated or clearly contradicted by context, e.g. a composition described herein as comprising a particular element should be understood as also describing a composition consisting of that element, unless otherwise stated or clearly contradicted by context. It will be further understood that the terms "comprises," "comprising," "includes" and / or "including," when used in this specification, specify the presence of stated features, integers, steps, operations, elements, and / or components, but do not preclude the presence or addition of one or more other features, integers, steps, operations, elements, components, and / or groups thereof.
[0067] As used herein, the singular forms "a," "an," and "the" are intended to include the plural forms, including "at least one," unless the content clearly indicates otherwise. "At least one" is not to be construed as limiting "a" or "an."
[0068] Unless otherwise defined, all terms used herein (including technical and scientific terms) have the same meaning as commonly understood by those skilled in the art to which this invention pertains. It will be further understood that terms, such as those defined in commonly used dictionaries, should be interpreted as having a meaning that is consistent with their meaning in the context of the relevant art and will not be interpreted in an idealized or overly formal sense unless expressly so defined in the present specification.
[0069] The invention will hereafter be described by way of the following non-limiting items.
[0070] The present invention relates to an insert device for insertion through an ostomy and / or anus of a human being, for application of pharmaceuticals locally in the intestine to a defined surface area. The device being configured to absorb intestinal fluid and waste inside the intestines of the human being, and / or configured to deliver pharmaceuticals to the intestines. The present invention further relates to various uses and methods of said device.
[0071] The intestinal insert device may release active substances by:A. the contact between the device surface, coated with active substances, with intestinal mucosa;
[0072] B. the absorption of intestinal fluids that causes the absorbent material to unfold and release embedded active substances to the intestine; and / or
[0073] C. C. the absorption of externally infused liquids containing active substances that causes the device to unfold and expose the intestinal mucosa for the active substances.
[0074] An intestinal insert device according to the invention may be used in an ostomy, stoma or a natural stoma. An ostomy or a stoma may be an artificially created opening in the body, or a natural opening. An example of a natural stoma is the anus, and an example of an artificial stoma is an ileostomy.
[0075] A pharmaceutical according to the invention, to be delivered through the device according to the invention, may be selected among a steroid, a probiotic, a non-steroid anti-inflammatory drug, a fecal transplant and an immunosuppressive.
[0076] Fecal microbiota transplantation or fecal matter transplant is used to remodel the intestinal micro-ecological balance in patients. Administration / delivery can be done with an absorbent anal or intestinal insert device.
[0077] According to an embodiment, the invention concerns an intestinal and / or anal insert device, wherein said device comprises a steroid distributed on the surface of the absorbent material, and wherein said device comprises a water-soluble coating enclosing the elongated body.
[0078] According to an embodiment, the invention concerns an intestinal and / or anal insert device, wherein said device comprises a probiotic distributed on the surface of the absorbent material, and wherein said device comprises a water-soluble coating enclosing the elongated body.
[0079] According to an embodiment, the invention concerns an intestinal and / or anal insert device, wherein said device comprises a non-steroid anti-inflammatory drug distributed on the surface of the absorbent material, and wherein said device comprises a water-soluble coating enclosing the elongated body.According to an embodiment, the invention concerns an intestinal and / or anal insert device, wherein said device comprises a fecal transplant distributed on the surface of the absorbent material, and wherein said device comprises a water-soluble coating enclosing the elongated body.
[0080] According to an embodiment, the invention concerns an intestinal and / or anal insert device, wherein said device comprises a immunosuppressive distributed on the surface of the absorbent material, and wherein said device comprises a water-soluble coating enclosing the elongated body.
[0081] According to an embodiment, the intestinal insert device of the invention comprises one active pharmaceutical agent.
[0082] According to a preferred embodiment, the intestinal insert device according to the invention comprises an expandable elongated body, wherein said expandable elongated body in said compressed state has a first diameter of about 0.5 - 1.8 cm, and a length of about 5-70 cm. This embodiment is suitable for anal insertion.
[0083] According to a preferred embodiment, the intestinal insert device according to the invention comprises an expandable elongated body, wherein said expandable elongated body in said compressed state has a first diameter of about 1 - 4.5 cm, and a length of about 20 - 70 cm. This embodiment is suitable for insertion into an ostomy.
[0084] Additionally, the present invention relates to an absorbent insert device for insertion through an ostomy and / or anus of a human being, the device being configured to absorb intestinal fluid and waste inside the intestines of the human being, the insert intestinal device may comprise: an expandable elongated body extending along a longitudinal direction of the absorbent insert intestinal device and having a stoma end and an oral end spaced from the stoma end along the longitudinal direction, wherein the expandable elongated body comprises one or more absorbent materials; one or more withdrawal means attached to the stoma end of the expandable elongated body; and one or more compression means configured to maintain the expandable elongated body in a compressed state, having a first diameter along the longitudinal direction, prior to insertion of the absorbent insert intestinal device through the ostomy and / oranus of the human being; wherein the expandable elongated body is configured to expand radially to a non-compressed state, having a second diameter along the longitudinal direction, when released from the one or more compression means upon insertion into the intestines of the human being through the ostomy and / or anus; wherein the second diameter is larger than the first diameter; wherein the expandable elongated body comprising the absorbent material is further configured to be pulled out of the intestines of the human being by means of the one or more withdrawal means. Particularly disclosed in where the one or more absorbent materials is at least one or more cellulose derivatives, especially wherein the one or more absorbent materials at least comprises carboxymethyl cellulose.
[0085] Intestinal fluid may also be termed intestinal liquid and intestinal output.
[0086] The stoma end may also be termed the anal or distal end and the oral end may also be called the proximal end.
[0087] By non-compressed is meant the size when the one or more absorbent materials in in their fully wetted state, i.e. the second diameter being the diameter when the expandable elongated body is fully wetted.
[0088] The second diameter may be measured when the device is in the fully saturated state, i.e. in the non-compressed state.
[0089] The stoma end of the intestinal insert device may also be termed the anal or distal end and the oral end may also be called the proximal end.
[0090] The absorbent material is preferably selected from one or more materials having a large absorbance capacity, i.e. the absorbency of the material is high. The material may further be selected from one or more materials which expands on absorption of liquids. By absorbency is meant absorbency assessed by any known method yielding absorbency in terms of weight per unit area, which preferably could be converted to absorbency in terms of weight ratio (g / g). Absorption could e.g. be measured by taking a sample measuring 5 cm times 5cm and weighing it (denoted Wl). The sample is then immersed in a physiological saline solution for 30 minutes at 37 degrees centigrade. The sample is then held to drip for 30 seconds before being weighed(denoted W2). Absorption (in g / g) is then equal to (W2-W1) / W1. Absorption (in g / cm2) is then equal to (W2-Wl) / area.
[0091] Preferably, the absorbent insert device is held in a compressed state prior to insertion through the stoma and / or anus of the subject, said compressed state ensuring that the insert device can be inserted through the stoma and / or anus. The insert device, in the compressed state, may have a cylindrical shape, preferably slightly conical with a smaller diameter at one end. The insert device may be compressed both longitudinally and radially. As an example, the insert device may have a diameter of approximately 1 to 3 cm and a length of approximately 5 to 20 cm in the compressed state. In its non-compressed state, the insert device could preferably obtain a diameter corresponding to the body canal of the subject (in case of the ileum of a person the diameter could be 2 to 5 cm) and a length of approximately 20 to 40 cm. The absorbent material may therefore be configured such that the diameter perpendicular to the longitudinal axis increases by at least 100% from the compressed state to the non-compressed state. Further, the absorbent material may be configured such that the longitudinal axis (the length of the absorbent material) is increased by at least 100% from the compressed state to the non-compressed state. Additionally, the absorbent material may be configured to expand such that the overall volume of the absorbent material in the non-compressed state is at least factor 4, such as a factor 8, larger than the volume of the absorbent material in the compressed state.
[0092] The compression means configured to maintain the expandable elongated body in a compressed state may be realised in a number of different ways, e.g. by a coating and / or an insertion sleeve enclosing the absorbent material. The coating is preferably water-soluble and configured to dissolve upon exposure to the moisture, intestinal fluids, and / or heat levels inside the subject. Accordingly, the insert device may comprise a coating and / or an insertion sleeve enclosing the absorbent material. As an example, the absorbent material may be compressed and wrapped in a polymer film, such as a water-soluble synthetic polymer film, the polymer film thereby constituting the coating. An example of a suitable polymer film is a poly(vinyl alcohol) (PVA) film. However, other coatings may be used. Alternatively, the device is compressed in an applicator and inserted and released inside the body canal, e.g. the small intestine. The applicator material may be paper, cardboard or plastic. Another insertion method consists of an insertion probe in terms of a catheter-like thin tube that is placed inside the absorbent insert intestinal device and guides the absorbent insert intestinal device into place whereby the probe is pulled out. Suitedmaterials for a probe / guiding catheter are latex, silicone, rubber, plastic or nitinol. Upon placement of the absorbent insert intestinal device inside the body canal, e.g. ileum or rectum, of the subject, the insert device is configured to expand to a size once the water-soluble coating is dissolved and / or the insertion sleeve is removed. The insert device preferably expands both in the radial and longitudinal direction.
[0093] By non-compressed is meant the size when the one or more absorbent materials in in their fully wetted state, i.e. the second diameter being the diameter when the expandable elongated body is fully wetted.
[0094] The absorbent insert intestinal device comprises an expandable elongated body. The elongated body may comprise or be made entirely from an absorbent material. Alternatively, the elongated body may form a receptacle, such as a tube, filled or partly filled with the one or more absorbent materials. The absorbent materials may be provided as a woven fabric, a nonwoven fabric, or a foam. An example of a nonwoven fabric is an air-laid paper.
[0095] In one or more embodiments, the expandable elongated body expands on the absorption of intestinal fluid and / or intestinal waste. This could be assessed by simply substituting the intestinal waste with an isotonic brine solution.
[0096] In one or more embodiments, the one or more absorbent materials is a compressed body of cellulose which has been chemically modified to increase its absorbency to at least 19g / g. This may be measured by a free swell method. The compressed body of (modified) cellulose will preferably expand on absorption of fluid.
[0097] In one or more embodiments, the insert device is a colostomy, an urostomy, an ileostomy, a jejunostomy or a rectal or anal device.
[0098] An ileostomy is an opening in the belly (abdominal wall) that is made during surgery. It is usually needed because a problem is causing the ileum to not work properly, or a disease is affecting that part of the colon and it needs to be removed. The end of the ileum (the lowest part of the small intestine) is brought through this opening to form a stoma. An ileostomy may only be needed for a short time (temporary), maybe for 3 to 6 months, because that part of the colonneeds time to rest and heal from a problem or disease. But sometimes a disease, such as cancer or inflammatory bowel disease, is more serious or chronic, and an ileostomy may be needed for the rest of a person's life (permanent). Besides usage in an ileostomy, the present invention can be used for other related purposes, such as preventing leakage from urostomies, colostomies, and jejunostomies. Sometimes jejunostomies and ileostomies are used interchangeably. Further envisioned may be the use of such device for the rectum, where it is used in connection with anal incontinence.
[0099] In one or more embodiments, the insert device is an ileostomy or a jejunostomy device.
[0100] In one or more embodiments, the insert device is for insertion through a colostomy, an urostomy, an ileostomy, or a jejunostomy.
[0101] In one or more embodiments, the insert device is for insertion through an ileostomy or a jejunostomy.
[0102] In one or more embodiments, the insert device is for insertion through anus.
[0103] In one or more embodiments, the insert device is for rectal insertion.
[0104] In one or more embodiments, the radial size of the expandable elongated body upon withdrawal near the ostomy and / or anus, is substantially equal to the radial size of the expandable elongated body in the compressed state, prior to insertion of the absorbent insert device through the ostomy and / or anus of the human being. In other words, the radial size of the expandable elongated body when removing the device preferably corresponds to the radial size in the compressed state. In this way there is certainty that the user can get the device out of the ostomy and anus.
[0105] It is important that the device is formed in such a way, so that retention or encapsulation of the fluid occurs. This can also be obtained by choosing the right absorbent material, as e.g. device / elongated body will experience a slight pressure when it is to be extracted through the stoma or anal opening .In one or more embodiments, the expandable elongated body has a first radial width along the longitudinal direction when the expandable elongated body is in the compressed state, and wherein the expandable elongated body comprising the absorbent material is further configured to conform to a second radial width when the absorbent insert intestinal device is pulled out of the intestines of the human being by means of the one or more withdrawal means, wherein the second radial width is substantially equal to the first radial length.
[0106] In one or more embodiments, the expandable elongated body is rigid when the expandable elongated body is in the compressed state and flexible when the expandable elongated body is in the non-compressed state. In a preferred embodiment, upon insertion, the device is rigid, and preferably no longer than 10 cm in the longitudinal direction.
[0107] By rigid is meant that it is unable to bend or be forced out of shape when applying a slight pressure by the user's hand. Small bending at higher amount of pressure applied is acceptable, however, it should be such that during normal use it will not bend to any major extend. By flexible is meant that it is capable of bending easily without breaking when only applying very little force to the device, such as e.g. holding it by hand in a horizontal alignment (e.g. bending under the pressure of gravity).
[0108] In one or more embodiments, the expandable elongated body changes from being rigid to being flexible when the expandable elongated body expands radially from the compressed state to the non-compressed state.
[0109] In one or more embodiments, the one or more absorbent materials are selected from materials being biodegradable. A biodegradable material is a material, which can undergo biodegradation, which is the breakdown of organic matter by microorganisms, such as bacteria and fungi. In other words, if something is biodegradable, then, given the right conditions and presence of microorganisms, fungi, or bacteria, it will eventually break down to its basic components and blend back in with the earth. Ideally, but not always, these substances degrade without leaving any toxins behind.
[0110] In one or more embodiments, the one or more absorbent materials at least comprises modified cellulose, such as chemically modified cellulose.The chemical modification may be carboxymethylation of cellulose, cotton, or a combination of the two and may be performed by contacting the material with a strong alkali, for example sodium hydroxide and a carboxymethylation agent such as chloroacetic acid or a salt thereof such as the sodium salt. These reagents may be applied to the material separately or together. The reaction is conveniently performed in an aqueous system which preferably comprises a water-miscible organic solvent such as ethanol or industrial methylated spirits in order to suppress swelling and dissolution of the carboxymethylated cellulose. A suitable method of conducting the modification is described in WO 00 / 01425. In a suitable method, the cellulosic body is loaded into a reaction vessel. Reaction fluid is pumped through the cellulosic material at 65 degrees centigrade for 90 minutes. The reaction fluid is a solution of an alkali (typically sodium hydroxide) and sodium monochloroacetate in industrial denatured alcohol. After the reaction time, the reaction is neutralised with acid and washed before being dried in a laboratory oven for 1 hour at 40 degrees centigrade.
[0111] In one or more embodiments, the one or more absorbent materials at least consists of a plurality of monomer units linked to each other via ether bonds, ester bonds, amide bonds, or combinations hereof, wherein said monomer units are selected from molecules having formula X:
[0112] OR
[0113]
[0114] , wherein R can be H, CH2COONa, CH2COOK, or CH2COOH.
[0115] In one or more embodiments, the one or more absorbent materials at least comprises a cellulose derivative selected from methyl cellulose (MC), hydroxypropyl cellulose (HPC), hydroxypropylmethyl cellulose (HPMC), ethyl cellulose (EC), sodium carboxymethyl cellulose (NaCMC), carboxymethyl cellulose (CMC), or combinations thereof.
[0116] In one or more embodiments, the one or more absorbent materials are in the form of a salt, such as a sodium or a potassium salt. A salt herein is a chemical compound consisting of an ionic assembly of positively charged cations and negatively charged anions, which results in acompound with no net electric charge. This can be a component ion such as the carboxylate (RCOCT) together with e.g. sodium (Na+).
[0117] In one or more embodiments, the one or more absorbent materials originate from one or more cellulose sources, such as one or more natural cellulose sources.
[0118] In one or more embodiments, the one or more absorbent materials are selected from carboxymethyl cellulose (CMC), alginate, super absorbent polymers (SAP), super absorbent fibres, plant fibres / polymers, or combinations thereof.
[0119] In one or more embodiments, the one or more absorbent materials at least comprises carboxymethyl cellulose.
[0120] In one or more embodiments, the one or more absorbent materials at least comprises carboxymethyl cellulose fibres having a degree of substitution of at least 0.1, such as a degree of substitution of at least 0.2, or such as a degree of substitution of at least 0.3. The degree of substitution (DS) of a polymer is the (average) number of substituent groups attached per base unit (in the case of condensation polymers) or per monomeric unit (in the case of addition polymers). The term has been mainly used in cellulose chemistry.
[0121] Sodium carboxymethylcellulose (CMC for short) is a kind of high-polymer cellulose ether made from natural cellulose by chemical modification. CMC thickener is a widely used and the most cost-effective thickening agent. As can be seen from the structure formula, there are three hydroxyl groups in each glucose unit, namely C2, C3, and C6 hydroxyl groups. The number of hydrogens in hydroxyl group of glucose unit replaced by carboxymethyl can be expressed by degree of substitution (DS). If all the three hydroxyl groups in each glucose unit are replaced by carboxymethyl, the degree of substitution can be defined as 3. The degree of substitute has a direct impact on the solubility, emulsibility, thickening property, stability, acid resistance and salt tolerance.
[0122] It is generally thought that Sodium carboxymethyl cellulose has better emulsifying property when the degree of substitution is 0.6-0.7. Furthermore, with the increase of DS, other properties can be improved accordingly. When the degree of substitution is over 0.8, theresistance to acids and salts can be remarkably enhanced. To high degree of substitution also makes the polymer soluble in e.g. water; hence, in one or more embodiments, the one or more absorbent materials at least comprises carboxymethyl cellulose fibres having a degree of substitution of no more than 0.8, such as a degree of substitution of no more than 0.7, or such as a degree of substitution of no more than 0.6.
[0123] In one or more embodiments, the one or more absorbent materials comprises at least 50% by weight of carboxymethyl cellulose compared to the total weight of the expandable elongated body, such as at least 60% by weight, such as at least 70% by weight, such as at least 80% by weight, or such as at least 90% by weight of carboxymethyl cellulose compared to the total weight of the expandable elongated body.
[0124] In one or more embodiments, the one or more absorbent materials is carboxymethyl cellulose.
[0125] In one or more embodiments, the carboxymethyl cellulose is in the form of a powder, fibre, nonwoven, gel, or combinations thereof.
[0126] In one or more embodiments, the carboxymethyl cellulose is in the form of rope shaped, sheet shaped, or combinations thereof.
[0127] In one or more embodiments, the carboxymethyl cellulose is in the form of sheets.
[0128] In one or more embodiments, the carboxymethyl cellulose is in the form of sodium carboxymethylcellulose fibres.
[0129] In one or more embodiments, the carboxymethyl cellulose fibres has a mass per unit area from 120 g / m2to 180 g / m2, such as 130 g / m2to 170 g / m2, such as 140 g / m2to 160 g / m2, or such as 145 g / m2to 155 g / m2. The mass per unit of the CMC material is measured according to ISO 9073-1:1989.
[0130] In one or more embodiments, the carboxymethyl cellulose fibres has a liquid absorption of at least 15 g per 100 cm2, such as a liquid absorption of at least 20 g / 100 cm2. The liquid absorption is measured according to EN 13726-1:2002.In one or more embodiments, the carboxymethyl cellulose fibres a tensile strength in its dry state (i.e. prior to wetting) of at least 3 Newton per centimetre, such as at least 5 N / cm, such as at least 10 N / cm, or such as at least 12 N / cm.
[0131] In one or more embodiments, the carboxymethyl cellulose fibres a tensile strength in its wet state (i.e. after wetting) of at least 0.2 Newton per centimetre, such as at least 0.3 N / cm, such as at least 0.4 N / cm, such as at least 0.5 N / cm, or such as at least 0.6 N / cm. The tensile strength (dry or wet) is both measured according to ISO 13934-1:2013.
[0132] In one or more embodiments, the carboxymethyl cellulose fibres has a loss on drying of no more than 25%, such as no more than 20%, or such as no more than 18%. The loss on drying is measured according to JYWN-QM-P02-SOP162.
[0133] In one or more embodiments, the one or more absorbent materials, such as carboxymethyl cellulose, has a heavy metal content of no more than 20 microgram per gram. The heavy metal content is measured according to JYWN-QM-P02-SOP162.
[0134] In one or more embodiments, the one or more absorbent materials further comprises alginate, cellulose, cotton, chitosan, or combination thereof.
[0135] In one or more embodiments, the expandable elongated body further comprises one or more antibacterial compounds, such as silver particles.
[0136] In one or more embodiments, the expandable elongated body further comprises one or more reinforcement materials.
[0137] In one or more embodiments, the one or more reinforcement materials are selected from nonwoven fibres, woven fibres, or combinations thereof.
[0138] In one or more embodiments, the one or more reinforcement materials are selected from nylon, polypropylene, cotton, cellulose material combined with fibres of polymer, or combinations thereof.In one or more embodiments, the one or more absorbent materials are selected from material having an intestinal fluid and waste absorbing capacity of at least 500%, such as at least 1000%, such as at least 2000%, or such as at least 3000%. These data could e.g. be obtained as described above, by weighing the material before and after absorption of intestinal fluids (or simply just isotonic water solution).
[0139] In one or more embodiments, the one or more absorbent materials are selected from material having a water absorbance capacity of at least a factor 5, such as a factor 10, such as at least a factor 20, or such as at least a factor 30.
[0140] In one or more embodiments, the first diameter is equal to or less than the diameter of the ostomy of the human being.
[0141] In one or more embodiments, the first diameter is equal to or less than the diameter of the anal opening of the human being.
[0142] In one or more embodiments, the second diameter is equal to or larger than the diameter of the intestines of the human being.
[0143] In one or more embodiments, the expandable elongated body is configured to be further compressed along the longitudinal direction by the ostomy upon insertion of the absorbent insert ostomy device through the ostomy of the human being.
[0144] In one or more embodiments, the second diameter is larger than the first diameter by at least a factor 1.25, such as by at least a factor 1.5, such as by at least a factor 1.75, such as by at least a factor 2, or such as by at least a factor 2.5.
[0145] In one or more embodiments, the ratio of the thickness of the expandable elongated body along the longitudinal direction pre-hydration to the thickness of the expandable elongated body along the longitudinal direction post hydration is greater than 1.25. The pre / post hydration thickness may be measured by a method described herein or by any known method to measure such.In one or more embodiments, the ratio of the thickness of the expandable elongated body along the longitudinal direction pre-hydration to the thickness of the expandable elongated body along the longitudinal direction post hydration is greater than 1.5, such as 1.75, such as 2, or such as greater than 2.5.
[0146] In one or more embodiments, the ratio of the thickness of the one or more absorbent materials along the longitudinal direction of the expandable elongated body pre-hydration to the thickness of the one or more absorbent materials along the longitudinal direction of the expandable elongated body post hydration is greater than 1.25. The pre / post hydration thickness may be measured by a method described herein or by any known method to measure such.
[0147] In one or more embodiments, the ratio of the thickness of the one or more absorbent materials along the longitudinal direction of the expandable elongated body pre-hydration to the thickness of the one or more absorbent materials along the longitudinal direction of the expandable elongated body post hydration is greater thanl.5, such as 1.75, such as 2, or such as greater than 2.5.
[0148] In one or more embodiments, the first diameter is 1.75 cm or less, such as 1.50 cm or less, or such as 1.25 cm or less.
[0149] In one or more embodiments, the first diameter is between 1.00 and 1.75 cm, such as between 1.00 and 1.50 cm, or such as between 1.00 and 1.25 cm.
[0150] In one or more embodiments, the second diameter is at least 2 cm, such as at least 2.5 cm, or such as at least 3 cm.
[0151] In one or more embodiments, the second diameter is between 2 and 5 cm, such as between 2 and 4 cm, such as between 2 and 3 cm, or such as between 2.5 and 4 cm.In one or more embodiments, the length of the expandable elongated body in the compressed state along the longitudinal direction is 20 cm or less, such as 17.5 cm or less, such as 15 cm or less, such as 12.5 cm or less, or such 10 cm or less.
[0152] In one or more embodiments, the length of the expandable elongated body in the noncompressed state along the longitudinal direction is at least 12.5 cm, such as at least 15 cm, such as at least 20 cm, such as at least 25 cm, such as at least 30 cm, such as at least 35 cm, or such as at least 40 cm.
[0153] In one or more embodiments, the expandable elongated body in the non-compressed state has a second diameter of at least 2 cm, such as from 2 to 5 cm, and length along the longitudinal direction of at least 20 cm, such as from 20 to 40 cm.
[0154] High absorption capacity may be needed from the device. It could be important that the device is able to absorb at least between 100 mL and 200 mL to provide value for the users, however, it may still be significantly compressed when being inserted (e.g. such as dimension of about 10x1.5 cm) to be able to enter through the stoma and / or anal opening without too much discomfort for the user. Because of this, it is preferred that the material has a high absorbency.
[0155] In one or more embodiments, the absorbent insert intestinal device has an absorption capacity of at least 50 millilitres, such as at least 75 millilitres, such as at least 100 millilitres, such as at least 125 millilitres, such as at least 150 millilitres, such as at least 175 millilitres, such as at least 200 millilitres, or such as at least 250 millilitres.
[0156] In one or more embodiments, the one or more absorbent materials has an absorption capacity of at least 50 millilitres, such as at least 75 millilitres, such as at least 100 millilitres, such as at least 125 millilitres, such as at least 150 millilitres, such as at least 175 millilitres, such as at least 200 millilitres, or such as at least 250 millilitres.
[0157] In one or more embodiments, the expandable elongated body is curled around the longitudinal axis to form a helix comprising a plurality of turns.In one or more embodiments, the expandable elongated body comprises a plurality of flexible protrusions extending radially from the body, such that the elongated body resembles a brush.
[0158] In one or more embodiments, the expandable elongated body is curled around the longitudinal axis to form a helix comprising a plurality of turns and further comprises a plurality of flexible protrusions extending radially from the body.
[0159] In one or more embodiments, the expandable elongated body is curled around the longitudinal axis to form a helix comprising a plurality of turns and further comprises a plurality of flexible protrusions extending radially from the body, wherein the plurality of flexible protrusions has a hair-like configuration.
[0160] In one or more embodiments, the elongated body is provided as a flexible tube, which is partly or entirely filled with the one or more absorbent materials. In one or more embodiments, the flexible tube is a woven crinoline tube comprising a material selected from the group of: nylon, polyester, polyvinylidene fluoride (PVDF), polypropylene, or combinations thereof.
[0161] In one or more embodiments, the expandable elongated body is formed from a sheet, which is rolled into an elongated conical shape.
[0162] In one or more embodiments, the expandable elongated body is formed from a tube having a closed end, said tube being folded one or more times inside itself, wherein the tube is configured to unfold upon pulling the device out of the ostomy and / or anus by use of the withdrawal means.
[0163] In one or more embodiments, the expandable elongated body comprises a plurality of cylinders, each cylinder comprising an absorbent material, and wherein withdrawal means is attached to each cylinder, such that the plurality of cylinders may be withdrawn from the subject individually.
[0164] In one or more embodiments, the expandable elongated body comprises a support structure configured to increase the longitudinal axial stability of the body, wherein said support structure comprises a material selected from the group of: silicone, rubber, latex, polyethylene, polyvinyl chloride, nitinol, or combinations thereof.In one or more embodiments, the absorbent insert device is to collect intestinal fluid and waste from the intestines of a subject.
[0165] In one or more embodiments, the absorbent insert intestinal device is for insertion through an ostomy of a human being.
[0166] In one or more embodiments, the absorbent insert intestinal device is an absorbent insert ostomy device.
[0167] In one or more embodiments, the modified cellulose is biodegradable.
[0168] In one or more embodiments, the modified cellulose at least comprises chemically modified cellulose.
[0169] In one or more embodiments, the modified cellulose consists of a plurality of monomer units linked to each other via ether bonds, ester bonds, amide bonds, or combinations hereof, wherein said monomer units are selected from molecules having formula X:
[0170] OR
[0171] !
[0172]
[0173] , wherein R can be H, CH2COONa, CH2COOK, or CH2COOH.
[0174] In one or more embodiments, the modified cellulose at least comprises a cellulose derivative selected from methyl cellulose (MC), hydroxypropyl cellulose (HPC), hydroxypropylmethyl cellulose (HPMC), ethyl cellulose (EC), sodium carboxymethyl cellulose (NaCMC), carboxymethyl cellulose (CMC), or combinations thereof.
[0175] In one or more embodiments, the modified cellulose is in the form of a salt, such as a sodium or a potassium salt.
[0176] In one or more embodiments, the modified cellulose originates from one or more cellulose sources, such as one or more natural cellulose sources.In one or more embodiments, the modified cellulose at least comprises carboxymethyl cellulose.
[0177] In one or more embodiments, the modified cellulose at least comprises carboxymethyl cellulose fibres having a degree of substitution of at least 0.1, such as a degree of substitution of at least 0.2, or such as a degree of substitution of at least 0.3.
[0178] In one or more embodiments, the modified cellulose at least comprises carboxymethyl cellulose fibres having a degree of substitution of no more than 0.8, such as a degree of substitution of no more than 0.7, or such as a degree of substitution of no more than 0.6.
[0179] In one or more embodiments, the modified cellulose at least comprises 50% by weight of carboxymethyl cellulose, such as at least 60% by weight, such as at least 70% by weight, such as at least 80% by weight, or such as at least 90% by weight of carboxymethyl cellulose.
[0180] In one or more embodiments, the carboxymethyl cellulose is in the form of a powder, fibre, nonwoven, gel, or combinations thereof.
[0181] In one or more embodiments, the carboxymethyl cellulose is in the form of rope shaped, sheet shaped, or combinations thereof.
[0182] In one or more embodiments, the carboxymethyl cellulose is in the form of sheets.
[0183] The absorbent insert intestinal device as disclosed herein may be produced using various methods. In one or more embodiments, two identical bands of absorbent material, such as CMC, are placed on top of each other. In a preferred embodiment, the length of each is from 50 cm to 100 cm, and the width of each is from 2.5 cm to 4.0 cm.
[0184] In one or more embodiments, parallel cuts are made in the whole length of the identical bands, from both sides perpendicular to the longitudinal direction, leaving a central spine that holds the identical bands together and creates a hair-like structure in the identical bands.In one or more embodiments, the two identical bands are then sewn together along the central spine with an elastic band that is stretched to 80-100% of the elastic bads maximal stretching capacity during the sewing process. In a preferred embodiment, the elastic band is attached to the full length of the identical bands and continues a further 10 cm to 30 cm from where the bands end, leaving a solitary elastic band string. Such string may be used as a withdrawal string, i.e. the one or more withdrawal means. Upon relaxation of the elastic band, the two identical bands, now sewed to the elastic band, will curl up into a spiral-shaped device of approximately 20 cm to 35 cm in length (depending on the initial length of the identical bands) with an appendix of approximately 10 cm to 30 cm of the elastic band without absorbent material.
[0185] In one or more embodiments, the absorbent insert intestinal device is then compressed into a length of 3 cm to 8 cm and a diameter of 0.5 cm to 1.8 cm, onto which a poly(vinyl alcohol) (PVA) film is wrapped around for permanently fixating the device in the compressed state.
[0186] In one or more embodiments, the device in the compressed state is inserted into the stoma and / or anus, whereby the secretion of the stoma causes the PVA film to dissolve. The device will then slowly expand in length and width as it absorbs the liquid faeces inside the intestines, hereby enabling a leak-tight (or semi-leak-tight) closure, by having a diameter of approximately 3 cm which is bigger than a typical stoma opening of 1.5 cm. The device is kept in place by the abdominal wall as the peristaltic movements pushes it towards the abdominal wall.
[0187] In one or more embodiments, the hair-like structure is configured to collect solid parts of food in the faeces, which can then be withdrawn from the intestine together with the liquid faeces, when removing the device from the stoma and / or anus. Further, the hair-like structure may ensure a large surface area of the absorbing material hereby ensuring a large absorption capacity.
[0188] In one or more embodiments, the size of the absorbent insert intestinal device is designed to fit the anatomical dimensions of a human intestine.
[0189] According to an embodiment, the invention concerns an intestinal insert device, the device being configured to absorb intestinal waste of a human being, the device comprising:
[0190] - an expandable elongated body comprising an absorbent material,- withdrawal means attached to the elongated body, and
[0191] - one or more pharmaceutical, microbiome, probiotic and / or faecal transplant, wherein said expandable elongated body is configured to expand radially and / or longitudinal to a non-compressed state,
[0192] wherein the length of the expandable elongated body in the non-compressed state is about 10 - 70 cm.
[0193] According to an embodiment the invention concerns an intestinal insert device, the device being configured to absorb intestinal waste of a human being, the device comprising:
[0194] - an expandable elongated body comprising an absorbent material,
[0195] - withdrawal means attached to the elongated body, and
[0196] - one or more pharmaceutical, microbiome, probiotic and / or faecal transplant, wherein said expandable elongated body is configured to expand radially and / or longitudinal to a non-compressed state,
[0197] wherein the length of the expandable elongated body in the non-compressed state, along the longitudinal axis is at least 10 cm.
[0198] According to an embodiment, the invention concerns the intestinal insert device, wherein said pharmaceutical is embedded as a gelatinous substance, a liquid substance or as a powder, into the absorbent material.
[0199] According to an embodiment, the invention concerns the intestinal insert device, wherein said pharmaceutical is incorporated as a gelatinous substance, a liquid substance or as a powder, into the absorbent material.
[0200] According to an embodiment, the invention concerns the intestinal insert device, wherein said pharmaceutical is embedded as a gelatinous substance, a liquid substance or as a powder, into or onto the absorbent material.
[0201] According to an embodiment, the invention concerns the intestinal insert device, wherein said pharmaceutical is riboflavin (vitamin B2). According to an embodiment, said riboflavin (vitamin B2) is in the form of a powder.
[0202] According to an embodiment, the invention concerns the intestinal insert device, wherein said device comprises one or more compression means; wherein the compression means isconfigured to maintain the expandable elongated body in a compressed state, wherein the elongated body is embedded with said one or more pharmaceutical, microbiome, probiotic and / or faecal transplant.
[0203] According to an embodiment, the invention concerns the intestinal insert device, wherein the expandable elongated body in said compressed state has a first diameter of about 0.1 - 2.5 cm.
[0204] According to an embodiment, the invention concerns the intestinal insert device, wherein the expandable elongated body in said compressed state has a first diameter of about 0.1 - 2.5 cm or 1.0 - 4.5 cm, or preferably about 0.5 - 1.8 cm.
[0205] According to an embodiment, the invention concerns the intestinal insert device, wherein the length of the expandable elongated body in the non-compressed state is about 10 - 70 cm, such as 10 - 15 cm or such as 20 - 70 cm.
[0206] According to an embodiment, the invention concerns the Intestinal insert device, wherein the compression means is configured to maintain the expandable elongated body in a compressed state, having a first diameter, prior to insertion; wherein the expandable elongated body is configured to expand radially to a non-compressed state, having a second diameter, when released from the compression means upon insertion into the intestine and / or anus; and wherein the first diameter is equal to or less than the diameter of the intestinal opening and / or anus of the human being and the second diameter is equal to or larger than the diameter of the intestinal opening of the human being.
[0207] According to an embodiment, the invention concerns the intestinal insert device, wherein the second diameter is between about 1 - 10 cm, 2-9 cm, 2-8 cm, 2-7 cm, 2-6 cm, 2 and 5 cm, 3-6 cm, 3 - 5 cm or preferably about 3-4 cm.
[0208] According to an embodiment, the invention concerns the intestinal insert device, wherein said expandable elongated body in said non-compressed state has a surface area of above 100 cm2, preferably above 150 cm2.
[0209] According to an embodiment, the invention concerns the intestinal insert device, wherein said expandable elongated body comprises a plurality of flexible protrusions extending radially fromthe body, or wherein the elongated body is curled around a longitudinal axis of the body to form a helix comprising a plurality of turns.
[0210] According to an embodiment, the invention concerns the intestinal insert device, wherein said expandable elongated body comprises 2 - 50 flexible protrusions, such as 5 - 45 flexible protrusions, such as 10 - 40 flexible protrusions, such as 15 - 35 flexible protrusions, such as 20 -30 flexible protrusions, extending radially from the body, or wherein the elongated body is curled around a longitudinal axis of the body to form a helix comprising 2 - 50, such as 5 - 45 turns, such as 10 - 40 turns, such as 15 - 35 turns, such as 20 - 30 turns.
[0211] According to an embodiment, the invention concerns the intestinal insert device, wherein said active pharmaceutical agent is released when the device is in said non-compressed state.
[0212] According to an embodiment, the invention concerns the intestinal insert device, wherein said expandable elongated body comprises a water-soluble coating, wherein said coating is a poly(vinyl alcohol) (PVA) film.
[0213] According to an embodiment, the invention concerns the intestinal insert device, wherein said pharmaceutical is selected among a steroid, a probiotic, a microbiome, a non-steroid antiinflammatory drug, a fecal transplant and an immunosuppressive.
[0214] According to an embodiment, the invention concerns the intestinal insert device, wherein said device comprises an expandable elongate body comprising an absorbent material, such as carboxymethyl cellulose.
[0215] According to an embodiment, the invention concerns the intestinal inert device, wherein the absorbent material comprises at least 50% by weight of carboxymethyl cellulose compared to the total weight of the expandable elongated body, such as at least 60% by weight, such as at least 70% by weight, such as at least 80% by weight, or such as at least 90% by weight of carboxymethyl cellulose compared to the total weight of the expandable elongated body.
[0216] According to an embodiment, the invention concerns an active pharmaceutical agent for use in the treatment of an intestinal disorder or disease for administration through the intestinal insert device described herein.When describing the embodiments, the combinations and permutations of all possible embodiments have not been explicitly described. Nevertheless, the mere fact that certain measures are recited in mutually different dependent claims or described in different embodiments does not indicate that a combination of these measures cannot be used to advantage. The present invention envisages all possible combinations and permutations of the described embodiments.
[0217] The present disclosure will now be described with reference to the accompanying drawings, in which preferred example embodiments of the disclosure are shown. The disclosure may, however, be embodied in other forms and should not be construed as limited to the herein disclosed embodiments. The disclosed embodiments are provided to fully convey the scope of the disclosure to the skilled person.
[0218] Various examples are described hereinafter with reference to the figures. It should also be noted that the figures are only intended to facilitate the description of the examples. They are not intended as an exhaustive description of the claimed invention or as a limitation on the scope of the claimed invention. In addition, an illustrated example needs not have all the aspects or advantages shown. An aspect or an advantage described in conjunction with a particular example is not necessarily limited to that example and can be practiced in any other examples even if not so illustrated, or if not so explicitly described.
[0219] Detailed description of the drawings
[0220] The above objects, as well as additional objects, features and advantages of the present disclosure will be more fully appreciated by reference to the following illustrative and nonlimiting detailed description of example embodiments of the present disclosure, when taken in conjunction with the accompanying drawings.
[0221] Fig. 1A shows the absorbent insert intestinal device according to one embodiment of the present disclosure. This figure illustrates the insert device when it is in a compressed state and when it is placed in the body canal of a subject. This embodiment of the insert device comprises an elongated body, which is curled around a longitudinal axis of the body to form a helix comprising a plurality of turns.Fig. IB shows the absorbent insert intestinal device according to another embodiment of the present disclosure. This figure illustrates the insert device when it is in a compressed state and when it is placed in the body canal of a subject. This embodiment of the insert device comprises an elongated body with a plurality of flexible protrusions extending radially from the body, such that the elongated body resembles a brush.
[0222] Fig. 1C shows the absorbent insert intestinal device according to another embodiment of the present disclosure. This figure illustrates the insert device when it is in a compressed state and when it is placed in the body canal of a subject. In this embodiment, the elongated body of the insert device is provided as a flexible tube, which is preferably partly or entirely filled with the absorbent material.
[0223] Fig. ID shows the absorbent insert intestinal device according to another embodiment of the present disclosure. This figure illustrates the insert device when it is in a compressed state and when it is placed in the body canal of a subject. In this embodiment, the elongated body of the insert device is formed from a sheet, which is rolled into an elongated conical shape.
[0224] Fig. IE shows the absorbent insert intestinal device according to another embodiment of the present disclosure. This figure illustrates the insert device when it is in a compressed state and when it is placed in the body canal of a subject. In this embodiment, the elongated body of the insert device is formed from a tube having a closed end, said tube being folded one or more times inside itself, wherein the tube is configured to unfold upon pulling the device out of the stoma and / or anus by use of the withdrawal means.
[0225] Fig. IF shows the absorbent insert intestinal device according to another embodiment of the present disclosure. This figure illustrates the insert device when it is in a compressed state and when it is placed in the body canal of a subject. In this embodiment, the elongated body of the insert device is formed from a plurality of cylinders, each cylinder comprising an absorbent material.
[0226] Figures 2A-2F shows a non-compressed state of the insert device according to the corresponding (compressed) embodiment of fig. 1A-1F. Hence, fig. 2A is the non-compressed (expanded) state of the embodiment shown in fig. 1A and so forth. For each of the embodiments, the insertdevice is preferably configured to expand to form a seal of the body canal, wherein it is placed, once the compression (e.g. provided by a coating or an insertion-sleeve) is removed. Further, it can be seen on all the figures, that the devices is shaped / configured such the diameter of the absorbent material at the cross-section of the stoma, upon removal, is substantially similar to the diameter of the stoma. This diameter is different from the diameter of the absorbent material as expanded in the non-compressed state.
[0227] Figures 3A-3F shows cross-sections of the embodiments shown in figures 1A-1F. These crosssections correspond to the compressed state of the insert device.
[0228] Figures 4A-4F shows cross-sections of the embodiments shown in figures 2A-2F. These crosssections correspond to the non-compressed state of the insert device.
[0229] Fig. 5A shows the absorbent insert intestinal device according to another embodiment of the present disclosure. This embodiment of the insert device comprises an elongated body, which is formed from a sheet that is folded to form a wave-like pattern of crests and troughs.
[0230] Fig. 5B shows the absorbent insert intestinal device according to another embodiment of the present disclosure. This embodiment of the insert device comprises an elongated body constituting a cylinder that is folded one or more times.
[0231] The cross-sections of figures 3A-3F are all drawn to scale in regards to the ratio with the crosssections of figures 4A-4F, i.e. the ratio between the diameter (the first diameter) of the crosssection of figure 3A-F and the diameter (the second diameter) of the cross-section of figure 4A-F, respectively, are correct. As exemplified, figure 3A has a cross-section where the diameter is approximate 2 cm (corresponding to the first diameter in the compressed state), whereas figure 4A has a cross-section where the diameter is approximately 4 cm (corresponding to the second diameter in the non-compressed state). This gives a ratio of 1 to 2 between the first and the second diameter of said embodiment. Similar calculation can be made based on the scale of the figures comparing 3B with 4B, 3C with 4C and so forth.
[0232] The absorbing organs shown in figure 1 A-F has been compressed radially to a diameter of 1 to 3 cm, preferably produced in different sizes to suit the variable sizes of intestinal openings. Theabsorbing organs shown in figure 1 A-C has been compressed longitudinally to a length of 5 to 20 cm (fig. 1 A-C). The absorbing organs shown in figure 1 D-F has not been compressed longitudinally and has the same length upon insertion as in their maximal absorbing state (fig. 2 D-F). All absorbing organs (fig. 1 A-F) are held in the compressed state by itself, after compression, by an insertion device or by a thin cover (or wrapping) 5 of a material that is disintegrable by water, intestinal fluids, or heat. Soon after the insertion into the intestine, the insertion device will be withdrawn or the cover 5 will dissolve or disintegrate, whereby the absorbing material expands upon absorption to a size limited by the design and dimensions of the absorbing organs (seen in fig. 3 A-C). Fig 2 A-F show that the absorbing organs in the expanded state has a pre-defined size and shape whereby a too high pressure on the intestinal wall 6 is avoided. The absorbing organ can be held within the intestine by means of the radial expansion of the organ when not affected by the compressing factor, whereby the diameter of the organ exceeds the size of the intestinal opening 7 (fig. 2 A-F).
[0233] Upon extraction, the absorbing organs can be extracted through an intestinal opening 7 of minimum 1 cm. To ensure the capability of safe extraction, the dimension of the absorbing organ upon extraction does not exceed the dimension of the compressed absorbing organ upon insertion.
[0234] Under compression of the absorbing organ, the cover or insertion device may be placed on it, e.g. by wrapping with PVA film in a single layer with a small overlapping at which the PVA film adheres to itself by a modest moistening. The mounting may also take place by slipping a tubular film or insertion device over the organ.
[0235] Figure 1-4 A shows an absorbing organ in the compressed (fig. 1 and 3) or expanded state (figure 2 and 4). This organ has a spiral shape, and when it has reached its maximal absorption capacity (fig. 2 A), it has a diameter of 2 to 3 cm and a length of 15 to 40 cm in the spiral-folded state. The diameter of the strand forming the spiral is 1 to 1.5 cm, whereby the spiral can be extracted through an intestinal opening 7 of minimum 1 cm. In the distal end of the spiral it has a withdrawal means 9 (here a string) string attached that is partly left outside the intestinal opening 7 upon insertion. This string is used to pull out the spiral in a long strand. The spiral shaped absorbing organ may consist, entirely or partly of a hydrophilic polymer foam, e.g. polyurethane foam which may be prepared from a mould or by cutting from a bigger block. Itcould also consist entirely or partly of nonwovens, carboxymethyl cellulose, alginate, super absorbent polymers, super absorbent fibres or plant fibres / polymers. For some of the materials it would be beneficial to build the spiral on a stiff spiral core 10 to keep the spiral shape. This core could be made of e.g. silicone, rubber, latex, polyethylene or polyvinyl chloride.
[0236] Figure 1-4 B shows an absorbing organ in the compressed (fig. 1 and 3) or expanded state (figure 2 and 4). This organ has the shape of a brush and when it has reached its maximal absorption capacity (fig. 2 B), it has a diameter of 2 to 3 cm and a length of 15 to 40 cm. The hairs of the brush are fixated on a core string 12 that is either solid or tubular. In order to extract the brush more easily through an intestinal opening 7 of minimum 1 cm, the core string 12 of the brush should preferable be resilient or elastic, so that the radial diameter of the brush is lowered upon extraction. A resilient or elastic core string 12 could be manufactured of e.g. silicone, rubber, latex, polyethylene or polyvinyl chloride. A stretchable core string 12 could also be a woven crinoline tube in materials as e.g. nylon, polyester, PVDF or polypropylene. The hairs of the brush may consist, entirely or partly of a hydrophilic polymer foam, e.g. polyurethane foam or nonwovens, carboxymethyl cellulose, alginate, super absorbent polymers, super absorbent fibres or plant fibres / polymers. In the distal end of the brush it has a withdrawal means 9 (here a string) attached that is partly left outside the intestinal opening 7 upon insertion. This string is used to pull out the brush and can be made of e.g. cotton.
[0237] Figure 1-4 C shows an absorbing organ in the compressed (fig. 1 and 3) or expanded state (figure 2 and 4). This organ has the shape of a tube and when it has reached its maximal absorption capacity (fig. 2 C), it has a diameter of 2 to 3 cm and a length of 15 to 40 cm. In order to extract the tube through an intestinal opening of minimum 1 cm, the tube should be expandable, so that the radial diameter of the tube is lowered upon extraction. The tube could be manufactured as a woven crinoline tube in materials as e.g. nylon, polyester, PVDF or polypropylene to keep a stiffness of the tube. The woven tube could be blended, coated or partly filled with absorbing material 13, 14, and 15 e.g. hydrophilic polymer foam, nonwovens, carboxymethyl cellulose, alginate, super absorbent polymers, super absorbent fibres or plant fibres / polymers. In the distal end of the tube it has a withdrawal means 9, 16 (here a string) attached that is partly left outside the intestinal opening upon insertion. This string is used to pull out the tube, and is made of e.g. cotton.Figure 1-4 D shows an absorbing organ in the compressed (fig. 1 and 3) or expanded state (figure 2 and 4). This organ has a conus shape and when it has reached its maximal absorption capacity (fig. 2 D), it has a largest diameter of 2 to 3 cm and a length of 15 to 40 cm. The absorbing conus is made of a rectangular sheet of absorbent material (e.g. 10x30 cm) that is rolled a bit skewed into a conus shape. Along one end of the sheet a withdrawal means 9, 16 is attached (here a string), that is partly left outside the intestinal opening 7 upon insertion. This string is used to pull out the conus. To extract the conus through an intestinal opening 7 of minimum 1 cm, the rolled sheet will unfold upon extraction whereby the sheet will be pulled out in one layer like a spiral. The conus may consist, entirely or partly of a hydrophilic polymer foam, e.g. polyurethane foam or nonwovens, carboxymethyl cellulose, alginate, super absorbent polymers, super absorbent fibres or plant fibres / polymers.
[0238] Figure 1-4 E shows an absorbing organ in the compressed (fig. 1 and 3) or expanded state (figure 2 and 4). This organ has the shape of a cylinder and when it has reached its maximal absorption capacity (fig. 2 E), it has a largest diameter of 2 to 3 cm and a length of 15 to 40 cm. The absorbing cylinder is made of a long tube in absorbing fabric (e.g. 2.5x60 cm) closed in one end and folded one or two times inside itself, to a length 1 / 2 or 1 / 3 of the initial tube. In the closed end of the tube a withdrawal means 9 is attached (here a string), that is partly left outside the intestinal opening 7 upon insertion. When pulling the string the cylinder unfolds to the long tube, whereby it can be extracted through an intestinal opening 7 of minimum 1 cm. The cylinder may consist, entirely or partly of a hydrophilic polymer foam, e.g. polyurethane foam or nonwovens, carboxymethyl cellulose, alginate, super absorbent polymers, super absorbent fibres or plant fibres / polymers. To keep the longitudinal length of the cylinder, it may be necessary to make some stiffening longitudinal seams or strings in nylon, polyester, PVDF or polypropylene. Figure 5 shows alternative folding options of this absorbing organ.
[0239] Figure 1-4 F shows an absorbing organ in the compressed (fig. 1 and 3) or expanded state (figure 2 and 4). This organ consists of three (or two or four) neighbouring cylinders and when they have reached their maximal absorption capacity (fig. 2 F), the organ has a largest diameter of 2 to 3 cm and a length of 15 to 40 cm. The absorbing cylinders may consist, entirely or partly of a hydrophilic polymer foam, e.g. polyurethane foam or nonwovens, carboxymethyl cellulose, alginate, super absorbent polymers, super absorbent fibres or plant fibres / polymers. In the end of every single cylinder, withdrawal means 9 are attached (here strings), that is partly leftoutside the intestinal opening 7 upon insertion. When pulling a string, only one cylinder is extracted, whereby it can be extracted through an intestinal opening 7 of minimum 1 cm. Extraction will remove all cylinders one by one (when repeated). The absorbing cylinders may consist, entirely or partly of a hydrophilic polymer foam, e.g. polyurethane foam which may be prepared from a mould or by cutting from a bigger block or tube. It could also consist entirely or partly of nonwovens, carboxymethyl cellulose, alginate, super absorbent polymers, super absorbent fibres or plant fibres / polymers. For some of the materials it would be beneficial to build the cylinder on a stiff core 17 to keep the longitudinal shape. This core could be made of e.g. silicone, rubber, latex, polyethylene or polyvinyl chloride. Another way to keep the longitudinal stiffness of the cylinder, would be to make some longitudinal seams or strings in nylon, polyester, PVDF or polypropylene.
[0240] Combinations of the described absorbing organs is possible. For example, a brush formed as a spiral or a smaller size brush (fig. 1-4 B) or tube (fig. 1-4 C) used as the cylinders in figure 1-4 F.
[0241] Figure 8 shows directions of the expandable elongated body 20 as disclosed herein. The figure shows the radial direction 21 in which the body is expanding when going from the compressed state to the non-compressed state. The figure further shows the longitudinal direction 22 in which the body preferably expands when going from the compressed state to the noncompressed state, and in which direction the body extents.
[0242] The compressed state is when the one or more absorbent materials are in a "dry" state, such as before absorption of liquid from the intestines and before removal of the compression means. This means that the dimension can be measured by placing the device in a fixated state (by one or more compression means) on a table and measuring the dimensions. The non-compressed state is when the one or more absorbent materials are fully "wetted" in liquid, such as after end absorption in the intestines. This means that the dimension can be measured by placing the device in a relaxed state on a table and measuring the dimensions after being fully wetted.
[0243] Further shown is how the diameter 23 (the first and the second diameter) should be measured. Lastly the figure shows the oral end 25 and the anal end 24, to which the withdrawal means 9 are attached in this embodiment.Fig. 7A shows any of the described embodiments, as disclosed herein, wherein the expandable elongated body 30 is in its compressed state. The body 30 is attached to a withdrawal mean 26 in the form of a string. Around the body 30 is wrapped a cover 29, which maintain the body 30 in its compressed state until the cover 29 is removed. The cover could e.g. be a PVA film, which would dissolve, when the device is inserted into the intestines.
[0244] Fig. 7B shows the absorbent insert intestinal device according to one embodiment of the present disclosure. This embodiment of the insert device comprises an elongated body 30, which is curled around a longitudinal axis of the body to form a helix comprising a plurality of turns. Further, the insert device comprises an elongated body with a plurality of flexible protrusions extending radially from the body 30, such that the elongated body 30 comprises a plurality of hair-like structures 31. The embodiment of 7B could effectively be seen as a combination of the embodiment of 1A and IB, with slight modifications. This further highlight that combinations of the described absorbing organs are possible.
[0245] The embodiment of f ig.7 B is further configured to expand to form a seal of the body canal, wherein it is placed, once the compression (e.g. provided by a coating or an insertion-sleeve) is removed.
[0246] Upon extraction, the absorbing organs can be extracted through an intestinal opening of minimum 1 cm. To ensure the capability of safe extraction, the dimension of the absorbing organ upon extraction does not exceed the dimension of the compressed absorbing organ upon insertion. Figure 7C shows how the device could look after extraction, where it can be seen how the elongated body 30 is further stretched, such that the winding of the spiral core 27 extends. This will happen when the device is extracted by pulling the withdrawal means 26.
[0247] The embodiment of fig. 7B shows a device, preferably comprised of at least four components, an absorbent material, such as sodium carboxymethylcellulose (CMC) dressing, an elastic band 26 formed from e.g. elastane and polyester, a thread for sewing 28, such as e.g. a polyester thread, and a film to coat the absorbent material, such as e.g. a PVA film.
[0248] The device may then be produced as follows: Two identical bands of the absorbent material are placed on top of each other, both having a length of 50-100 cm and a width of 2.5-4.0 cm.Parallel cuts are made in the whole length of the bands, from both sides perpendicular to the longitudinal direction, leaving a central spine that holds the bands together and creates the so-called "hairs", shown in the figure as hair-like structures 31. The two bands are then sewn together along the central spine 28, with an elastic band 26 that is stretched to 80-100% of maximal stretching capacity during the sewing process. The elastic band 26 is attached to the full length of the bands and continues a further 10-30 cm from where the bands end, leaving a solitary elastic band string to be used as a withdrawal string 26. Upon relaxation of the elastic band, the bands curl up into a spiral-shaped device 27 of approximately 20-35 cm in length with an appendix 26 of approximately 10-30 cm of the elastic band without absorbent material. The device is then compressed into a length of 3-8 cm and a diameter of 0.5-1.8 cm, onto which a PVA film is wrapped, permanently fixating the device in the compressed state. When the compressed device is inserted into the stoma, the secretion of the intestine causes the PVA film to dissolve. The absorbent body 30 then slowly expands in length and width as it absorbs the liquid faeces. The spiral shape 27 enables the tampon to function as a leak-tight (or semi-leak-tight) closure, by having a diameter of approximately 3 cm which is bigger than a typical stoma opening of 1.5 cm, whereas the tampon is kept in place by the abdominal wall when the peristaltic movements push it towards the abdominal wall. The small hair-like structures 31 collect solid parts of food in the faeces, which can then be withdrawn from the intestine together with the liquid faeces. They also ensure a large surface area of the absorbing material ensuring a large absorption capacity.
[0249] Fig. 8A shows the absorbent insert intestinal device according to one embodiment of the present disclosure. This figure illustrates the insert device when it is in a compressed state and when it is placed in the body canal of a subject. This embodiment of the insert device comprises an elongated body, which is curled around a longitudinal axis of the body to form a helix comprising a plurality of turns. This embodiment of the insert device further comprises the elongated body with a plurality of flexible protrusions extending radially from the body, such that the elongated body additionally resembles a brush.
[0250] Figure 8B show a non-compressed state of the insert device according to the corresponding (compressed) embodiment of fig. 8A. For the embodiments, the insert device is preferably configured to expand to form a seal of the body canal, wherein it is placed, once the compression (e.g. provided by a coating or an insertion-sleeve) is removed. Further, it can beseen on the figure, that the device is shaped / configured such the diameter of the absorbent material at the cross-section of the stoma, upon removal, is substantially similar to the diameter of the stoma. This diameter is different from the diameter of the absorbent material as expanded in the non-compressed state.
[0251] The absorbing organ shown in figure 8A has been compressed radially to a diameter of 1 to 3 cm, preferably produced in different sizes to suit the variable sizes of intestinal openings. The absorbing organ shown in figure 8A has been compressed longitudinally to a length of 5 to 20 cm. The absorbing organ is held in the compressed state by itself, after compression, by an insertion device or by a thin cover (or wrapping) of a material that is disintegrable by water, intestinal fluids, or heat. Soon after the insertion into the intestine, the insertion device will be withdrawn or the cover will dissolve or disintegrate, whereby the absorbing material expands upon absorption to a size limited by the design and dimensions of the absorbing organ (seen in fig. 8B). Fig 8A shows that the absorbing organ in the expanded state has a pre-defined size and shape whereby a too high pressure on the intestinal wall 6 is avoided. The absorbing organ can be held within the intestine by means of the radial expansion of the organ when not affected by the compressing factor, whereby the diameter of the organ exceeds the size of the intestinal opening 7.
[0252] Upon extraction, the absorbing organ can be extracted through an intestinal opening 7 of minimum 1 cm. To ensure the capability of safe extraction, the dimension of the absorbing organ upon extraction does not exceed the dimension of the compressed absorbing organ upon insertion.
[0253] Under compression of the absorbing organ, the cover or insertion device may be placed on it, e.g. by wrapping with PVA film in a single layer with a small overlapping at which the PVA film adheres to itself by a modest moistening. The mounting may also take place by slipping a tubular film or insertion device over the organ.
[0254] Figure 8A-B shows an absorbing organ in the compressed (figure 8A) or expanded state (figure 8B). This organ has a spiral shape, and when it has reached its maximal absorption capacity (fig.
[0255] 8B), it has a diameter of 2 to 3 cm and a length of 15 to 40 cm in the spiral-folded state. The diameter of the strand forming the spiral is 1 to 1.5 cm, whereby the spiral can be extractedthrough an intestinal opening 7 of minimum 1 cm. In the distal end of the spiral it has a withdrawal means 9 (here a string) attached that is partly left outside the intestinal opening 7 upon insertion. This string is used to pull out the spiral in a long strand. The spiral shaped absorbing organ may consist, entirely or partly of a hydrophilic polymer foam, e.g. polyurethane foam which may be prepared from a mould or by cutting from a bigger block. It could also consist entirely or partly of nonwovens, carboxymethyl cellulose, alginate, super absorbent polymers, super absorbent fibres or plant fibres / polymers. For some of the materials it would be beneficial to build the spiral on a stiff spiral core to keep the spiral shape. This core could be made of e.g. silicone, rubber, latex, polyethylene or polyvinyl chloride. The shown absorbing organ further has on the outside of the spiral shape a brush shape, such that when it has reached its maximal absorption capacity (fig. 8B), it has a diameter of 2 to 3 cm and a length of 15 to 40 cm. The hairs of the brush are fixated on either the core string or extend outside the helical core. In order to extract the brush more easily through an intestinal opening 7 of minimum 1 cm, the core string of the brush should preferable be resilient or elastic, so that the radial diameter of the brush is lowered upon extraction. A resilient or elastic core string could be manufactured of e.g. silicone, rubber, latex, polyethylene, or polyvinyl chloride. A stretchable core string could also be a woven crinoline tube in materials as e.g. nylon, polyester, PVDF or polypropylene. The hairs of the brush may consist, entirely or partly of a hydrophilic polymer foam, e.g. polyurethane foam or nonwovens, carboxymethyl cellulose, alginate, super absorbent polymers, super absorbent fibres or plant fibres / polymers.References
[0256] 5, 29 - Cover
[0257] 6 - Intestinal wall
[0258] 7 - Intestinal opening
[0259] 9, 16, 26 - Withdrawal means
[0260] 10, 27 - Spiral core
[0261] 12, 28 - Core string
[0262] 13, 14, 15 - Absorbing material 17 - Stiff core
[0263] 20, 30 - Expandable elongated body 21 - Radial direction
[0264] 22 - Longitudinal direction
[0265] 23 - Diameter (e.g. first and second) 24 - Anal end
[0266] 25 -Oral end
[0267] 31 - hair-like structureItems:
[0268] 1) An intestinal insert device, wherein said device comprises a pharmaceutical, a microbiome, a probiotic, or a faecal transplant.
[0269] 2) An intestinal insert device according to item 1, the device being configured to absorb intestinal waste of a human being, the device comprising:
[0270] - an expandable elongated body comprising an absorbent material,
[0271] - withdrawal means attached to the elongated body, and
[0272] - one or more active pharmaceutical agents.
[0273] 3) The intestinal insert device according to any of the preceding items, wherein said active pharmaceutical agent is embedded as a gelatinous substance, a liquid substance or as a powder, into the absorbent material.
[0274] 4) The intestinal insert device according to any of the preceding items, wherein said device comprises one or more compression means; wherein the compression means is configured to maintain the expandable elongated body in a compressed state, wherein the elongated body is embedded with said one or more active pharmaceutical agents.
[0275] 5) The intestinal insert device according to any of the preceding items, wherein said expandable elongated body is configured to expand radially and / or longitudinal to a non-compressed state.
[0276] 6) The intestinal insert device according to any of the preceding items, wherein the expandable elongated body in said compressed state has a first diameter of about 0.1 - 2.5 cm or preferably about 0.5 - 1.8 cm
[0277] 7) The intestinal insert device according to any of the preceding items, wherein the length of the expandable elongated body in the non-compressed state is about 10 - 70 cm, such as 10 - 15 cm, such as 20 - 70 cm.8) The intestinal insert device according to any of the preceding items, wherein the expandable elongated body in said compressed state has a first diameter of about 1.0 - 4.5 cm in diameter.
[0278] 9) The intestinal insert device according to any of the preceding items, wherein the length of the expandable elongated body in the non-compressed state is about 20 - 70 cm.
[0279] 10) The intestinal insert device according to any of the preceding items, wherein said expandable elongated body in said non-compressed state has a surface area of above 100 cm2, preferably above 150 cm2.
[0280] 11) The intestinal insert device according to any of the preceding items, wherein said expandable elongated body comprises a plurality of flexible protrusions extending radially from the body, such that the elongated body resembles a brush, or wherein the elongated body is curled around a longitudinal axis of the body to form a helix comprising a plurality of turns.
[0281] 12) The intestinal insert device according to any of the preceding items, wherein said active pharmaceutical agent is released when the device is in said non-compressed state.
[0282] 13) The intestinal insert device according to any of the preceding items, wherein said expandable elongated body comprises a water-soluble coating, wherein said coating is a poly(vinyl alcohol) (PVA) film.
[0283] 14) An active pharmaceutical agent for use in the treatment of an intestinal disorder or disease for administration through the intestinal insert device according to any of the preceding items.
[0284] 15) A pharmaceutical for use in the treatment of a disorder or disease for administration through an intestinal insert device.16) A steroid and / or a probiotic and / or a non-steroid anti-inflammatory drug and / or a fecal transplant and / or an immunosuppressive pharmaceutical and / or antibiotic for use in the treatment of a disorder or disease for anal administration or administration through an intestinal insert device.
[0285] 17) A steroid for use in the treatment of a disorder or disease for administration through an intestinal insert device.
[0286] 18) The steroid according to any of the preceding items, wherein said steroid is selected among a corticosteroid, prednisolone, hydrocortisone, prednisone, betamethasone, tixocortol, budesonide, beclomethasone, cortisone, or methylprednisolone.
[0287] 19) A probiotic for use in the treatment of a disorder or disease for administration through an intestinal insert device.
[0288] 20) The probiotic according to any of the preceding items, wherein said probiotic is selected among a Lactobacillus, Bifidobacterium, Saccharomyces, Streptococcus, Enterococcus, Escherichia, and Bacillus.
[0289] 21) A non-steroid anti-inflammatory drug for use in the treatment of a disorder or disease for administration through an intestinal insert device.
[0290] 22) The non-steroid anti-inflammatory drug according to any of the preceding items, wherein said non-steroid anti-inflammatory drug is selected among acetylated salicylates, non-acetylated salicylates, propionic acids, acetic acids, enolic acids, anthranilic acids, naphthylalanine, and selective COX-2 inhibitors.
[0291] 23) The non-steroid anti-inflammatory drug according to any of the preceding items, wherein said non-steroid anti-inflammatory drug is an aminosalicylate.
[0292] 24) The non-steroid anti-inflammatory drug according to any of the preceding items, wherein said non-steroid anti-inflammatory drug is selected among sulfasalazine, mesalazine, olsalazine, balsalazide, acetylsalicylic acid, celecoxib, diclofenac, diflunisal,etodolac, etoricoxib, fenoprofen, flurbiprofen, ibuprofen, indomethacin, ketoprofen, ketorolac, meclofenamate, mefenamic acid, meloxicam, nabumetone, naproxen, oxaprozin, piroxicam, rofecoxib, salsalate, sulindac, tolmetin, valdecoxib.
[0293] 25) The immunosuppressive according to any of the preceding items, wherein said immunosuppressive is selected among azathioprine, mercaptopurine, methotrexate, a small molecule, tofacitinib, upadacitinib and ozanimed.
[0294] 26) The antibiotic according to any of the preceding items, wherein said antibiotic is selected among ciprofloxacin and metronidazole.
[0295] 27) A fecal transplant for use in the treatment of a disorder or disease for administration through an intestinal insert device.
[0296] 28) The steroid and / or probiotic and / or non-steroid anti-inflammatory drug and / or fecal transplant and / or an immunosuppressive according to any of the preceding items, wherein the device is for insertion in an ileostomy, and / or in a colostomy and / or for anal insertion.
[0297] 29) The steroid and / or probiotic and / or non-steroid anti-inflammatory drug and / or a fecal transplant and / or an immunosuppressive according to any of the preceding items, wherein the device is not for vaginal insertion.
[0298] 30) The steroid and / or probiotic and / or non-steroid anti-inflammatory drug and / or fecal transplant and / or an immunosuppressive according to any of the preceding items, wherein said administration is an administration through an ileostomy, and / or in an colonostomy and / or for anal administration.
[0299] 31) The steroid and / or probiotic and / or non-steroid anti-inflammatory drug and / or fecal transplant and / or an immunosuppressive according to any of the preceding items, wherein said disorder or disease is selected among a disease of the intestinal tract or an inflammatory state of the intestinal tract.32) The steroid and / or probiotic and / or non-steroid anti-inflammatory drug and / or fecal transplant and / or an immunosuppressive according to any of the preceding items, wherein said disorder or disease is selected among a cancer, an inflammatory bowel disease, haemorrhoids, diverticulitis, colon irritable or condyloma acuminatum.
[0300] 33) The steroid and / or probiotic and / or non-steroid anti-inflammatory drug and / or fecal transplant and / or an immunosuppressive according to any of the preceding items, wherein said disorder or disease is selected among colon cancer, morbus crohn and ulcerative colitis.
[0301] 34) An intestinal insert device, wherein said device comprises the steroid and / or a probiotic and / or a non-steroid anti-inflammatory drug and / or a fecal transplant and / or an immunosuppressive according to any of the preceding items.
[0302] 35) An intestinal insert device according to any of the preceding items, wherein said device comprises said steroid and / or probiotic and / or non-steroid anti-inflammatory drug and / or fecal transplant and / or an immunosuppressive.
[0303] 36) The intestinal insert device according to any of the preceding items, wherein said device comprises an elongated body.
[0304] 37) The intestinal insert device according to any of the preceding items, wherein said device comprises a water-soluble coating.
[0305] 38) The intestinal insert device according to any of the preceding items, wherein said water- soluble coating is enclosing the elongated body.
[0306] 39) The intestinal insert device according to any of the preceding items, wherein said water- soluble coating is configured to dissolve upon exposure to the moisture and / or heat levels inside the subject.40) The intestinal insert device according to any of the preceding items, wherein said water- soluble coating is a poly(vinyl alcohol) (PVA) film.
[0307] 41) The intestinal insert device according to any of the preceding items, wherein said device is coated with a plastic film or a foil.
[0308] 42) The intestinal insert device according to any of the preceding items, wherein said device comprises an expandable elongate body comprising an absorbent material, such as carboxymethyl cellulose.
[0309] 43) The intestinal insert device according to any of the preceding items, wherein said absorbent material is selected among cellulose derivative selected from methyl cellulose (MC), hydroxypropyl cellulose (HPC), hydroxypropylmethyl cellulose (HPMC), ethyl cellulose (EC), sodium carboxymethyl cellulose (NaCMC), carboxymethyl cellulose (CMC) and combinations thereof.
[0310] 44) The intestinal insert device according to any of the preceding items, wherein said absorbent material is selected among carboxymethyl cellulose (CMC), alginate, super absorbent polymers (SAP), super absorbent fibres, plant fibres / polymers and combinations thereof.
[0311] 45) The Intestinal insert device according to any of the preceding items, wherein the expandable elongated body is configured to also expand radially to have a diameter along the longitudinal direction that is larger than the diameter was before insertion into the intestine.
[0312] 46) The Intestinal insert device according to any of the preceding items, wherein said device comprises withdrawal means attached to the elongated body.
[0313] 47) The Intestinal insert device according to any of the preceding items, wherein said device comprises one or more compression means.48) The Intestinal insert device according to any of the preceding items, wherein said device is for insertion through an ileostomy and / or anus of a human being, the device being configured to absorb intestinal waste inside the intestine of the human to form a leak- tight closure of the stoma and / or anal opening, the device comprising: an expandable elongated body comprising an absorbent material, and withdrawal means attached to the elongated body, wherein the expandable elongated body is configured to expand radially upon insertion into the intestine through the ostomy and / or anus, and wherein the elongated body comprises a plurality of flexible protrusions extending radially from the body, such that the elongated body resembles a brush.
[0314] 49) The Intestinal insert device according to any of the preceding items, wherein the elongated body of the insert device is formed from a tube having a closed end, said tube being folded one or more times inside itself, wherein the tube is configured to unfold upon pulling the device out of the intestine by use of the withdrawal means.
[0315] 50) The Intestinal insert device according to any of the preceding items, wherein the compression means is configured to maintain the expandable elongated body in a compressed state, having a first diameter, prior to insertion; wherein the expandable elongated body is configured to expand radially to a non-compressed state, having a second diameter, when released from the compression means upon insertion into the intestine and / or anus ; and wherein the first diameter is equal to or less than the diameter of the intestinal opening and / or anus of the human being and the second diameter is equal to or larger than the diameter of the intestinal opening (e.g. ileum and rectum) of the human being.
[0316] 51) The Intestinal insert device according to any of the preceding items, wherein the second diameter is between about 1 to 10 cm, 2-9 cm, 2-8 cm, 2-7 cm, 2-6 cm, 2 and 5 cm, 3-6 cm, 3 - 5 cm or preferably about 3-4 cm.
[0317] 52) The Intestinal insert device according to any of the preceding items, wherein the second diameter is about 2 cm, 3 cm, 4 cm, 5 cm, 6 cm, 7 cm, 8 cm, 9 cm or about 10 cm.) The Intestinal insert device according to any of the preceding items, wherein the length of the expandable elongated body in the non-compressed, and fully saturated state along the longitudinal axis is at least 5 cm, at least 10 cm, at least 15 cm, at least 20 cm, at least 30 cm or at least 40 cm.
[0318] ) The intestinal insert device according to any of the preceding items, wherein the length of the expandable elongated body in the non-compressed, and fully saturated state along the longitudinal axis is about 10 - 70 cm, about 20-70 cm, about 15-70cm, about 25-70 cm, about 30-70 cm, about 15 - 60 cm, about 20 - 55 cm, about 25 - 50, about 30 - 40, about 15 - 20 cm, about 30 - 40 cm, about 40 - 50, about 50 - 60, about 60 - 70 or preferably at least 50 cm.
[0319] ) The Intestinal insert device according to any of the preceding items, wherein said steroid and / or probiotic and / or non-steroid anti-inflammatory drug and / or fecal transplant and / or an immunosuppressive covers at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95% or preferably at least 99% of the surface of said device.
[0320] ) The Intestinal insert device according to any of the preceding items, wherein said steroid and / or probiotic and / or non-steroid anti-inflammatory drug and / or fecal transplant and / or immunosuppressive is embedded into the absorbent material and released upon unfolding of the device.
[0321] ) The Intestinal insert device according to any of the preceding items, wherein said steroid and / or probiotic and / or non-steroid anti-inflammatory drug and / or fecal transplant and / or immunosuppressive is embedded as a gelatinous substance into the absorbent material and released in a non-compressed state.
[0322] ) The Intestinal insert device according to any of the preceding items, wherein said steroid and / or probiotic and / or non-steroid anti-inflammatory drug and / or fecal transplant and / or immunosuppressive is embedded as a powder into the absorbent material and released in a non-compressed state.59) The Intestinal insert device according to any of the preceding items, wherein said steroid and / or probiotic and / or non-steroid anti-inflammatory drug and / or fecal transplant and / or immunosuppressive is infused as a liquid before or after the insertion of the device to be absorbed into the absorbent material causing the device to unfold to a noncompressed state and expose the active substance.
[0323] 60) The Intestinal insert device according to any of the preceding items, wherein said steroid and / or probiotic and / or non-steroid anti-inflammatory and / or fecal transplant and / or immunosuppressive is integrated in the absorbent material and released upon unfolding and / or wetting of the device.
[0324] 61) The Intestinal insert device according to any of the preceding items, wherein the device is placed in an applicator, and configured to be released from said applicator.
[0325] 62) The Intestinal insert device according to any of the preceding items, wherein the insert device comprises an expandable elongated body extending along a longitudinal direction of the Intestinal insert device and having a stoma end (or an anal end) and an oral end spaced from the stoma end (or anal opening) along the longitudinal direction.
[0326] 63) The Intestinal insert device according to any of the preceding items, wherein the expandable elongated body comprises one or more absorbent materials.
[0327] 64) A method of treating a disease or disorder, comprising administering one or more of the steroid and / or probiotic and / or non-steroid anti-inflammatory drug and / or fecal transplant and / or immunosuppressive according to any of the previous items formulated with an insert device according to any of the previous items.
[0328] 65) The method according to any of the previous items, comprising administering to the intestine a compound according any of the preceding items, formulated with an insert device according to any of the previous items.
[0329] 66) The method according to any of the previous items, wherein said disease is selected among a disease of the intestinal tract, an inflammatory state of the intestinal tract,ulcerative colitis, a cancer, an inflammatory bowel disease, haemorrhoids, diverticulitis, colon irritable or condyloma acuminatum, colon cancer, morbus crohn and ulcerative colitis.
[0330] 67) A steroid and / or a probiotic and / or a non-steroid anti-inflammatory drug and / or a fecal transplant and / or an immunosuppressive for use in the treatment of a disorder or disease for administration through an intestinal insert device according to any of the preceding items.
[0331] 68) A method comprising:
[0332] a. Identifying a mammal having an intestinal disorder,
[0333] b. Treating said mammal by:
[0334] i. Administering an intestinal insert device according to any of the preceding items to said mammal, and
[0335] ii. Administering a pharmaceutical according to any of the preceding items via said intestinal insert device,
[0336] Wherein said treatment reduces an inflammatory state of the intestinal tract.
[0337] Additional items
[0338] 1) An intestinal insert device, wherein said device comprises a pharmaceutical, a microbiome, a probiotic, or a faecal transplant.
[0339] 2) An intestinal insert device according to additional item 1, the device being configured to absorb intestinal waste of a human being, the device comprising:
[0340] - an expandable elongated body comprising an absorbent material,
[0341] - withdrawal means attached to the elongated body, and
[0342] - one or more pharmaceutical, microbiome, probiotic and / or faecal transplant.
[0343] 3) The intestinal insert device according to any of the preceding additional items, wherein said pharmaceutical is embedded as a gelatinous substance, a liquid substance or as a powder, into the absorbent material.4) The intestinal insert device according to any of the preceding additional items, wherein said device comprises one or more compression means; wherein the compression means is configured to maintain the expandable elongated body in a compressed state, wherein the elongated body is embedded with said one or more pharmaceutical, microbiome, probiotic and / or faecal transplant.
[0344] 5) The intestinal insert device according to any of the preceding additional items, wherein said expandable elongated body is configured to expand radially and / or longitudinal to a non-compressed state.
[0345] 6) The intestinal insert device according to additional items 4 or 5, wherein the expandable elongated body in said compressed state has a first diameter of about 0.1 - 2.5 cm or preferably about 0.5 - 1.8 cm
[0346] 7) The intestinal insert device according to additional items 5-6, wherein the length of the expandable elongated body in the non-compressed state is about, 5-70 cm, 10 - 70 cm, such as 10 - 15 cm, such as 20 - 70 cm.
[0347] 8) The intestinal insert device according to additional items 4 or 5, wherein the expandable elongated body in said compressed state has a first diameter of about 1.0 - 4.5 cm in diameter.
[0348] 9) The intestinal insert device according to additional items 5 or 8, wherein the length of the expandable elongated body in the non-compressed state is about 20 - 70 cm.
[0349] 10) The intestinal insert device according to any of the preceding items, wherein said expandable elongated body in said non-compressed state has a surface area of above 100 cm2, preferably above 150 cm2.
[0350] 11) The intestinal insert device according to any of the preceding items, wherein said expandable elongated body comprises a plurality of flexible protrusions extending radially from the body, or wherein the elongated body is curled around a longitudinalaxis of the body to form a helix comprising a plurality of turns.
[0351] 12) The intestinal insert device according to any of the preceding items, wherein said active pharmaceutical agent is released when the device is in said non-compressed state.
[0352] 13) The intestinal insert device according to any of the preceding items, wherein said expandable elongated body comprises a water-soluble coating, wherein said coating is a poly(vinyl alcohol) (PVA) film.
[0353] 14) The intestinal insert device according to any of the preceding items, wherein said pharmaceutical is selected among a steroid, a probiotic, a microbiome, a non-steroid anti-inflammatory drug, a fecal transplant and an immunosuppressive.
[0354] 15) An active pharmaceutical agent for use in the treatment of an intestinal disorder or disease for administration through the intestinal insert device according to any of the preceding items.Examples
[0355] The present invention is further illustrated by the following examples, which are not to be construed as limiting the scope of protection.
[0356] Example 1: An intestinal insert device made of carboxymethyl cellulose, for rectal administration has been tested on healthy volunteers. As the volunteers were healthy, the device did not comprise any pharmaceuticals. The test revealed that the device expands to a non-compressed state, upon rectal administration. Thus, proving that the device is fully functional for rectal administration.
[0357] Example 2: To produce the device as described herein, a pharmaceutical may be distributed over the elongated body of an insert device, and wrapped with a water-soluble coating, such as a poly(vinyl alcohol) (PVA) film. 1). The insert device as described herein may comprise an expandable elongated body that comprises one or more absorbent materials, such as carboxymethyl cellulose.
[0358] Example 3 (to be carried out at a later time): An insert device as described in example 1, wherein said pharmaceutical is substituted with a colouring agent is placed in the intestine of a pig. The water-soluble coating enclosing the device will dissolve upon exposure to the moisture of the intestine, and the colouring agent will be shown on the inside of intestine, illustrating the administration of a pharmaceutical.
[0359] Example 4: An insert device made of carboxymethyl cellulose was covered with riboflavin (vitamin B2) in the form of a powder, before the insert device was compressed and wrapped with a water-soluble coating. The tested product had a length of 8 cm and a diameter of 1,5 cm in the compressed state. The device was then placed in a see-through plastic bag, filled with water, illustrating how the device will unfold to its non-compressed state, while absorbing fluid. The device is placed in the bag from the left; thus, the left side of the picture illustrates an intestinal opening. The riboflavin powder is fluorescent, illustrating that the powder is released in the entire length of the insert device when the device is unfolded (non-compressed), see figure 9 (top). This way the device can deliver the pharmaceutical (in this example riboflavin powder), far into the intestines. In this example, the pharmaceutical is delivered in the entire length of 23 cm. Additionally, a commercial vaginal tampon (Tampax®, made of rayon and cotton, having a diameter of 1,3 cm and a length of 5 cm in compressed form) powdered withriboflavin (vitamin B2), is shown in figure 9 (bottom). This tampon simply delivers the pharmaceutical in a length of 8 cm._
[0360] Example 5: An insert device made of carboxymethyl cellulose was covered with riboflavin (vitamin B2) in the form of a powder, before the insert device was compressed. The device was then placed in a see-through plastic bag with perforations. This bag was then placed in a second see-through plastic bag filled with water. This illustrates how the device unfolds to its noncompressed state, while absorbing fluid, and releasing the powder in the entire length of the device. This is illustrated in figure 10.
Claims
Claims:1) An intestinal insert device, the device being configured to absorb intestinal waste of a human being, the device comprising:- an expandable elongated body comprising an absorbent material,- withdrawal means attached to the elongated body, and- one or more pharmaceutical, microbiome, probiotic and / or faecal transplant, wherein said expandable elongated body is configured to expand radially and / or longitudinal to a non-compressed state,wherein the length of the expandable elongated body in the non-compressed state is about 10 - 70 cm.2) The intestinal insert device according to claim 1, wherein said pharmaceutical is embedded as a gelatinous substance, a liquid substance or as a powder, into the absorbent material.3) The intestinal insert device according to any one of the preceding claims, wherein said device comprises one or more compression means; wherein the compression means is configured to maintain the expandable elongated body in a compressed state, wherein the elongated body is embedded with said one or more pharmaceutical, microbiome, probiotic and / or faecal transplant.4) The intestinal insert device according to claim 3, wherein the expandable elongated body in said compressed state has a first diameter of about 0.1 - 2.5 cm.5) The intestinal insert device according to any one of the preceding claims, wherein the length of the expandable elongated body in the non-compressed state is about 10 - 70 cm, such as 10 - 15 cm or such as 20 - 70 cm.6) The Intestinal insert device according to any one of claims 3-5, wherein the compression means is configured to maintain the expandable elongated body in a compressed state, having a first diameter, prior to insertion; wherein the expandable elongated body is configured to expand radially to a non-compressed state, having asecond diameter, when released from the compression means upon insertion into the intestine and / or anus; and wherein the first diameter is equal to or less than the diameter of the intestinal opening and / or anus of the human being and the second diameter is equal to or larger than the diameter of the intestinal opening of the human being.7) The Intestinal insert device according to claim 6, wherein the second diameter is between about 1 - 10 cm, 2-9 cm, 2-8 cm, 2-7 cm, 2-6 cm, 2 and 5 cm, 3-6 cm, 3 - 5 cm or preferably about 3-4 cm.8) The intestinal insert device according to any one of the preceding claims, wherein said expandable elongated body in said non-compressed state has a surface area of above 100 cm2, preferably above 150 cm2.9) The intestinal insert device according to any one of the preceding claims, wherein said expandable elongated body comprises a plurality of flexible protrusions extending radially from the body, or wherein the elongated body is curled around a longitudinal axis of the body to form a helix comprising a plurality of turns.10) The intestinal insert device according to any one of the preceding claims, wherein said active pharmaceutical agent is released when the device is in said non-compressed state.11) The intestinal insert device according to any one of the preceding claims, wherein said expandable elongated body comprises a water-soluble coating, wherein said coating is a poly(vinyl alcohol) (PVA) film.12) The intestinal insert device according to any one of the preceding claims, wherein said pharmaceutical is selected among a steroid, a probiotic, a microbiome, a non-steroid anti-inflammatory drug, a fecal transplant and an immunosuppressive.13) The intestinal insert device according to any one of the preceding claims, wherein said device comprises an expandable elongate body comprising an absorbent material, such as carboxymethyl cellulose.14) The intestinal inert device according to any one of the preceding claims, wherein the absorbent material comprises at least 50% by weight of carboxymethyl cellulose compared to the total weight of the expandable elongated body, such as at least 60% by weight, such as at least 70% by weight, such as at least 80% by weight, or such as at least 90% by weight of carboxymethyl cellulose compared to the total weight of the expandable elongated body.15) An active pharmaceutical agent for use in the treatment of an intestinal disorder or disease for administration through the intestinal insert device according to any one of the preceding claims.
